

Express Mail No. EM531526223US

FORM PTO-1390
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

15675P381

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/980291

INTERNATIONAL APPLICATION NO.
PCT/FR00/01447

INTERNATIONAL FILING DATE
May 26, 2000

PRIORITY DATE CLAIMED
May 27, 1999

TITLE OF INVENTION

NOVEL ANTIOXIDANTS, PREPARATION PROCESSES AND THEIR USES - UTILITY

APPLICANT(S) FOR DO/EO/US

Joel Oiry; Jean-Yves Puy; Jean-Louis Imbach; Pascal Clayette; Philippe Fretier

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
- ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A subsequent specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

priority request; preliminary examination report; forms pct/ib 301, 304, pct filing receipt; formal drawings transmittal; 22 drawings sheets

US

Annex US.II, page 2 PCT Applicant's Guide - Volume II - National Chapter - US

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/980291		INTERNATIONAL APPLICATION NO. PCT/FR00/01447		ATTORNEY'S DOCKET NUMBER 15675P381	
---	--	---	--	---------------------------------------	--

<p>17. <input type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by EPO or JPO \$1040.00</p> <p>International preliminary examination fee (37CFR1.482)not paid to USPTO but International Search Report prepared by the EPO or JPO. . . . \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p> <p style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:15%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> <th style="width:25%;"></th> </tr> <tr> <td>Total claims</td> <td>109 - 20 =</td> <td>89</td> <td>X \$18.00</td> <td>\$ 1602.00</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>X \$84.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$280.00</td> <td>\$ 280.00</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 2772.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">SUBTOTAL =</td> <td>\$ 2772.00</td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL NATIONAL FEE =</td> <td>\$ 2772.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property</td> <td>\$</td> </tr> <tr> <td colspan="4" style="text-align: right;">TOTAL FEES ENCLOSED =</td> <td>\$ 2772.00</td> </tr> <tr> <td colspan="4"></td> <td>\$ Amount to be: refunded</td> </tr> <tr> <td colspan="4"></td> <td>\$ charged</td> </tr> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	109 - 20 =	89	X \$18.00	\$ 1602.00	Independent claims	1 - 3 =	0	X \$84.00	\$ 0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$280.00				\$ 280.00	TOTAL OF ABOVE CALCULATIONS =				\$ 2772.00	Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	SUBTOTAL =				\$ 2772.00	Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	TOTAL NATIONAL FEE =				\$ 2772.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$	TOTAL FEES ENCLOSED =				\$ 2772.00					\$ Amount to be: refunded					\$ charged	<p>CALCULATIONS FOR PTO USE ONLY</p>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																			
Total claims	109 - 20 =	89	X \$18.00	\$ 1602.00																																																																		
Independent claims	1 - 3 =	0	X \$84.00	\$ 0.00																																																																		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$280.00				\$ 280.00																																																																		
TOTAL OF ABOVE CALCULATIONS =				\$ 2772.00																																																																		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$																																																																		
SUBTOTAL =				\$ 2772.00																																																																		
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$																																																																		
TOTAL NATIONAL FEE =				\$ 2772.00																																																																		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$																																																																		
TOTAL FEES ENCLOSED =				\$ 2772.00																																																																		
				\$ Amount to be: refunded																																																																		
				\$ charged																																																																		

a. ☒ A check in the amount of \$ 2772.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 022666. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Blakely, Sokoloff, Taylor & Zafman LLP
12400 Wilshire Blvd. 7th Floor
Los Angeles, CA 90025-1026

SIGNATURE

Eric S. Hyman
NAME

30,139
REGISTRATION NUMBER

US

Annex US.II, page 2 PCT Applicant's Guide - Volume II - National Chapter - US

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 097/980291		INTERNATIONAL APPLICATION NO. PCT/FR00/01447		ATTORNEY'S DOCKET NUMBER 15675P381	
---	--	--	--	--	--

17. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482 nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by EPO or JPO \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO. \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS FOR PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="text-align: right;">\$ 890.00</div>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	109 - 20 =	89	X \$18.00	\$ 1602.00	
Independent claims	1 - 3 =	0	X \$84.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00	\$ 280.00
TOTAL OF ABOVE CALCULATIONS =				\$ 2772.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$ 2772.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$ 2772.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$
TOTAL FEES ENCLOSED =				\$ 2772.00	
				\$ Amount to be refunded	\$
				charged	\$

a. ☒ A check in the amount of \$ 2772.00 to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 022666. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Blakely, Sokoloff, Taylor & Zafman LLP
 12400 Wilshire Blvd. 7th Floor
 Los Angeles, CA 90025-1026

SIGNATURE

 Eric S. Hyman
 NAME
 30,139
 REGISTRATION NUMBER

WO 00173266

22 | prb - 1 -

PCT/FR00/01447

NOVEL ANTIOXIDANTS, PREPARATION PROCESSES
AND THEIR USES

5 The present invention relates to novel compounds
possessing antioxidant activity, to their processes of
preparation and to their uses, in particular in the
preparation of medicaments intended to increase the
intracellular and/or extracellular level of glutathione
(GSH).

10

An increasing number of studies are showing that
reactive oxygen species play an important role in many
biological processes and in particular in the
development of many human pathologies and more
15 particularly in retroviral infections by the human
immunodeficiency virus (HIV).

20

Reactive oxygen species (ROS, superoxide ion, hydrogen
peroxide, hypochlorous ion, hydroxyl radicals, and the
like) are natural products of variable origin; they
originate from activated inflammatory cells, cells
which metabolize xenobiotics or cells exposed to
specific environmental milieus, such as cigarette
smoke.

25

Various substances are known for being active in
scavenging these reactive oxygen species at the
intracellular or extracellular level.


30

Mention may be made, for example, of glutathione, which
is a tripeptide (L- γ -glutamyl-L-cysteinylglycine, GSH)
found in all eukaryote cells. It is synthesized and
decomposed in the cell, mainly via its reduced form,
GSH. This reduced tripeptide, which participates in
35 many cell functions, such as, for example, protein and
nucleic acid synthesis, and the transportation of amino
acids, constitutes the main mechanism for intracellular
defense against oxidative stress. The factors which


promote the formation of reactive oxygen species lead to the consumption of the glutathione reserves.

5 N-Acetyl-L-cysteine (NAC) has been known for many years as a medicament for the cornea, as an antidote to poisoning by acetaminophen and as a mucolytic agent by cleaving the disulfide bonds in mucoproteins. Because NAC is used therapeutically in many pathologies in which oxidizing agents seem to play a role, it has been
10 suggested that it operates as an antioxidant. The mechanism of action of NAC is based on its ability to reduce extracellular cystine to cysteine or to be a source of SH (thiol functional group) metabolites. As a source of SH groups, NAC stimulates the synthesis of
15 GSH, enhances the glutathione S-transferase activity, promotes detoxification and acts directly on reactive oxidizing species. NAC and, by extension, the acylated variants of the amino acid L-cysteine are an excellent source of SH groups and are converted in the body into
20 metabolites capable of stimulating the synthesis of glutathione, thus promoting detoxification and acting directly as scavengers of reactive oxygen species.


In view of the central role of GSH in cell detoxification mechanisms, numerous alternatives targeted at
25 raising its intracellular level have been envisaged as adjuvant therapeutic strategy in numerous human pathologies and more particularly in infection by the human immunodeficiency virus (HIV) in recent years
30 (WO 92/21368; WO 95/10268; US 4 927 808; US 5 580 577). The problem was first of all approached by seeking to supplement the deficient molecule. Subsequent approaches were targeted at feeding the γ -glutamyl cycle. Thus, L-cysteine, GSH itself, NAC,
35 2-oxothiazolidine-4(R)-carboxylic acid (OTC) and cysteamine (MEA), the formulae of which are reproduced below, were tested as potential adjuvants for antiretrovirals in the treatment of infections by the HIV.




L-Cysteine



GSH



NAC




OTC



MEA

5 The beneficial effects of these molecules have been
 limited *in vivo* by low bioavailability, excessively
 rapid metabolization and insufficient concentrations
 which can be administered. NAC, for example, is a
 relatively labile molecule which, during its rapid
 decomposition, releases compounds comprising malodorous
 10 sulfides, such as H₂S. This problem of instability has
 limited the use of NAC or other compounds providing a
 source of -SH, such as L-cysteine or its acylated
 variants, in the preparation of formulations which can
 be used in pharmacology, dermatology or cosmetics.

15 The inventors have now developed novel compounds,
 capable of acting on the intracellular or extracellular
 level of glutathione, which do not exhibit the
 instability which was found for the known products.
 20 This is why a subject matter of the present invention
 is the compounds of following general formula (I):




25 and in which:

- R and R' independently represent a linear or branched C₁-C₇ alkyl radical or an aryl group which is unsubstituted or substituted by one or more radicals chosen from halogens, linear or branched C₁-C₃ alkyl radicals and -OH (hydroxyl) radicals;
 - R'' is hydrogen or a CO-R¹ group in which R¹ is a linear or branched C₁-C₇ alkyl radical or an aryl group which is unsubstituted or substituted by one or more radicals chosen from halogens, linear or branched C₁-C₃ alkyl radicals and -OH radicals;
- and the dimers formed by a disulfide bridge from one and/or other of the two sulfur atoms of the molecule of general formula I composed of the R'' radicals or of the R'CO- radicals of the two molecules, and the corresponding thiazolidine forms.

The R, R' and R'' alkyl radicals are preferably C₁-C₃ radicals. The halogens are preferably chlorine and fluorine.

In these compounds, NAC and MEA are combined and are or are not protected by biolabile groups.

According to a preferred embodiment, the present invention relates to a compound of general formula I such that R is a methyl group (-CH₃). In a more preferred embodiment, the present invention relates to a compound of general formula I such that R and R' are methyl groups (-CH₃). In the preferred embodiment, the invention relates to the compound known as N-(N-acetyl-L-cysteiny)-S-acetylcysteamine, known below as **I-152**, such that, in the general formula I, R and R' are methyl groups (-CH₃) and R'' is hydrogen.



This compound is particularly advantageous for its properties, which render it active in the treatment and/or prevention of pathologies or disorders related to an intra- and/or extracellular depletion in glutathione, in particular the treatment of viral infections and more particularly infections by the human immunodeficiency virus (HIV).

According to another preferred embodiment, the invention relates to the compound known as N-(N,S-bisacetyl-L-cysteinyl)-S-acetylcysteamine, known below as **I-176**, such that, in the general formula I, R and R' are methyl groups (-CH₃) and R'' is an acetyl group (-COCH₃).

According to another preferred embodiment, the invention relates to the compound known as N-(N-acetyl-S-isobutyryl-L-cysteinyl)-S-acetylcysteamine, known below as **I-177**, such that, in the general formula I, R and R' are methyl groups (-CH₃) and R'' is an isobutyryl group (-COCH(CH₃)₂).

According to another preferred embodiment, the invention relates to the compound known as N-(N-acetyl-S-pivaloyl-L-cysteinyl)-S-acetylcysteamine, known below as **I-178**, such that, in the general formula I, R and R' are methyl groups (-CH₃) and R'' is a pivaloyl group (-COC(CH₃)₃).

It is also one of the objects of the present invention to provide a compound of general formula I in which R is a methyl group (-CH₃) and R' is selected from the isopropyl group (-CH(CH₃)₂), the tert-butyl group (-C(CH₃)₃) and the phenyl group (-C₆H₅); such a compound preferably exhibits an R'' group selected from hydrogen (-H), the acetyl group (-COCH₃), the isobutyryl group (-COCH(CH₃)₂), the pivaloyl group (-COC(CH₃)₃) or the benzoyl group (-CO-C₆H₅). More particularly, the

invention is targeted at providing the compound below known as:

- **I-188**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is hydrogen ($-\text{H}$).
- **I-189**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the acetyl group ($-\text{COCH}_3$).
- **I-190**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- **I-191**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- **I-192**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
- **I-193**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is hydrogen ($-\text{H}$).
- **I-194**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the acetyl group ($-\text{COCH}_3$).
- **I-195**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- **I-196**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- **I-197**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
- **I-198**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is phenyl group ($-\text{C}_6\text{H}_5$) and R'' is hydrogen ($-\text{H}$).
- **I-199**, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and

R'' is the acetyl group ($-\text{COCH}_3$).

- I-200, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- 5 • I-201, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- I-202, such that, in the general formula I, R is a methyl group ($-\text{CH}_3$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and
10 R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).

It is also one of the objects of the present invention to provide a compound of general formula I which constitutes an intermediate in the synthesis of the
15 compound I-152, of its acylated derivatives or of its analogues. Thus, the invention also relates to the compound of general formula I known as 10 in which R is a methyl group ($-\text{CH}_3$), R' is the isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is a trityl group. The invention also
20 relates to the compound of general formula I known as 11 in which R is a methyl group ($-\text{CH}_3$), R' is the tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is a trityl group. The invention also relates to the compound of general formula I known as 12 in which R is a methyl group
25 ($-\text{CH}_3$), R' is the phenyl group ($-\text{C}_6\text{H}_5$) and R'' is a trityl group.

It is also one of the objects of the present invention to provide a compound of general formula I in which R
30 is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$); such a compound of the invention is preferably characterized in that R' is selected from the methyl group ($-\text{CH}_3$), the isopropyl group ($-\text{CH}(\text{CH}_3)_2$), the tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and the phenyl group ($-\text{C}_6\text{H}_5$); such a compound preferably
35 exhibits an R'' group selected from hydrogen ($-\text{H}$), the acetyl group ($-\text{COCH}_3$), the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$), the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$) or the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$). The invention is more particularly targeted at providing the compound below

known as:

- I-203, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group ($-\text{CH}_3$) and R'' is hydrogen ($-\text{H}$).
- 5 • I-204, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group ($-\text{CH}_3$) and R'' is the acetyl group ($-\text{COCH}_3$).
- I-205, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group
- 10 ($-\text{CH}_3$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- I-206, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group ($-\text{CH}_3$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- I-207, such that, in the general formula I, R is an
- 15 isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group ($-\text{CH}_3$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
- I-208, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is hydrogen ($-\text{H}$).
- 20 • I-209, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the acetyl group ($-\text{COCH}_3$).
- I-210, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is an isopropyl group
- 25 ($-\text{CH}(\text{CH}_3)_2$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- I-211, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
- 30 • I-214, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is hydrogen ($-\text{H}$).
- I-215, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a tert-butyl group
- 35 ($-\text{C}(\text{CH}_3)_3$) and R'' is the acetyl group ($-\text{COCH}_3$).
- I-216, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).

0980291-1120000

- I-217, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- I-218, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
- I-219, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is hydrogen ($-\text{H}$).
- I-220, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the acetyl group ($-\text{COCH}_3$).
- I-221, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$).
- I-222, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$).
- I-223, such that, in the general formula I, R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a phenyl group ($-\text{C}_6\text{H}_5$) and R'' is the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).

It is also one of the objects of the present invention to provide a compound of general formula I which constitutes an intermediate in the synthesis of the compound I-152, of its acylated derivatives or of its analogues. Thus, the invention also relates to the compound of general formula I known as **14** in which R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is a methyl group ($-\text{CH}_3$) and R'' is a trityl group. The invention also relates to the compound of general formula I known as **15** in which R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is the isopropyl group ($-\text{CH}(\text{CH}_3)_2$) and R'' is a trityl group. The invention also relates to the compound of general formula I known as **16** in which R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is the tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and R'' is a trityl group. The invention also relates to the compound of general formula I known as

17 in which R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$), R' is the phenyl group ($-\text{C}_6\text{H}_5$) and R~ is a trityl group.

5 The invention relates to the various compounds of the invention mentioned above in the thiazolidine form. The invention relates more particularly to the compounds I-212 and I-213, the chemical formula of which is given in scheme 5 below.

10 The invention relates to the compounds of formula I in the free form.

15 Another subject matter of the present invention is a process for the preparation of the compounds of general formula (I) according to processes analogous to those used in peptide synthesis.

20 According to a first way of preparing the compounds of the invention, the process according to the invention comprises the following stages:

- a) protection of the N-acyl-L-cysteine to provide the N-acyl-S-trityl-L-cysteine compound;
- b) coupling of the N-acyl-S-trityl-L-cysteine with the S-acylcysteamine hydrochloride to provide the N-(N-acyl-S-trityl-L-cysteiny)-S-acylcysteamine compound.

30 Still according to a first way of preparing, the compounds of the invention in thiazolidine form can be prepared according to the process which comprises the following stages:

- a) protection of the N-acyl-L-cysteine to provide the N-acyl-S-trityl-L-cysteine compound; then
- b) coupling of the protected N-acyl-S-trityl-L-cysteine with thiazolidine;

35 The compounds thus obtained can be subjected to the following stages of:

- c) deprotection of said compound obtained in the

- preceding stage b), then
- d) releasing the free thiol of formula (I).

Thus, according to a preferred embodiment, the process
5 for the preparation of compounds of the invention
comprises the stages of:

- a) protection of the N-acyl-L-cysteine to provide the
N-acyl-S-trityl-L-cysteine compound;
- b) coupling of the N-acyl-S-trityl-L-cysteine with
10 the S-acylcysteamine hydrochloride to provide the
N-(N-acyl-S-trityl-L-cysteiny)-S-acylcysteamine
compound;
- c) S-detritylation reaction of the N-(N-acyl-S-
trityl-L-cysteiny)-S-acylcysteamine compound, in
15 solution of methanol and chloroform, with a
mixture of silver nitrate, pyridine and methanol
to provide the corresponding silver sulfide;
- d) suspending said corresponding silver sulfide in
chloroform and then releasing of the free thiol in
20 the presence of HCl or H₂S.

More particularly, the preparation of the compound I-
152 of the invention can be carried out by the
preceding process; to do this, said N-acyl-S-trityl-L-
25 cysteine compound of stage a) is N-acetyl-S-trityl-L-
cysteine and said S-acylcysteamine hydrochloride of
stage b) is S-acetylcysteamine hydrochloride.

An additional S-acylation stage can be attached to the
30 preceding process for the preparation of compounds
according to the invention.

According to a second embodiment, the process according
to the invention, suitable for the preparation of the
35 compound of general formula I in which R = R' and R'' is
a hydrogen, comprises the following stages:

- a) esterification of the carboxyl functional group of
N-Boc-L-serine (1) with N-hydroxysuccinimide in
N,N-dimethylformamide (DMF) in the presence of

1,3-dicyclohexylcarbodiimide (DCC) to form the active ester (1'); then,

b) *in situ* condensation of the active ester formed (1') with ethanolamine (2) to provide the compound

5 N-(N-Boc-L-seryl)-2-aminoethanol (3); then,

c) Mitsunobu reaction on the compound (3) with triphenylphosphine and diisopropyl azodicarboxylate in the presence of thiocarboxylic acid in tetrahydrofuran to provide the compound N-(N-Boc-S-acyl-L-cysteinyl)-S-acylcysteamine (4); in the context of the preparation of the compound I-512, the thiocarboxylic acid is thioacetic acid; then,

10 d) deprotection of the compound (4) with trifluoroacetic acid.

15


In a specific embodiment, the invention relates to two processes for the preparation of the compound I-152.

20 The first process for the preparation of the compound I-152 (scheme 1) corresponds to the process for the preparation of the compound of general formula (I) described above and involves correctly protected L-cysteine. This preparation process is characterized in that it comprises the following stages (i) of coupling of N-acetyl-S-trityl-L-cysteine (7) with S-acetylcysteamine hydrochloride to provide the compound N-(N-acetyl-S-trityl-L-cysteinyl)-S-acetylcysteamine (8); then (ii) of S-detritylation reaction of the compound N-(N-acetyl-S-trityl-L-cysteinyl)-S-acetyl-

25 cysteamine, in solution in methanol and chloroform, with a mixture of silver nitrate, pyridine and methanol to provide the corresponding silver sulfide (9); then (iii) of suspending said corresponding silver sulfide in chloroform; then (iv) of release of the free thiol

30 in the presence of HCl or H₂S.

35



Scheme 1: Route 1.


Method A: Coupling, via a mixed anhydride formed in situ, of N-acetyl-S-trityl-L-cysteine (7) with S-acetylcysteamine hydrochloride; Method B: same coupling reaction, via an activated ester formed in situ, of 7. (b) S-detritylation with formation of the corresponding silver sulfide. (c) Release of the free thiol.

- Method A is based on the formation, in situ, of a mixed anhydride by reaction of 7 with isobutyl chloroformate in AcOEt in the presence of N-methylmorpholine (NMM). The anhydride is subsequently condensed with S-acetylcysteamine, released from its hydrochloride by NMM, to provide a8 with a yield, after treatments, of 55%.
- Method B uses, in situ, the N-succinimidyl active ester of 7 which, after condensation with S-acetylcysteamine, released from its hydrochloride by NMM, makes it possible to obtain 8 with a yield, after treatments, of 70%. The active ester was formed by reaction of the preceding mixed anhydride (method A) with N-hydroxysuccinimide in AcOEt.

The compound 8, in solution in methanol and chloroform, is subsequently S-detritylated by treatment with a mixture composed of silver nitrate, pyridine and methanol to provide the corresponding silver sulfide 9. This sulfide, which can be isolated, is then suspended

in CHCl_3 and then HCl (the use of H_2S leads to the same result) is added to release the free thiol I-152.


The second process for the preparation of the compound I-152 (scheme 2) uses L-serine, N-protected by a t-butoxycarbonyl (Boc) (1), as starting material.



10 Scheme 2: Route 2. (a) Coupling of N-Boc-L-serine, via
an activated ester formed *in situ*, with ethanolamine.
(b) Mitsunobu reaction, with a thioacid, on the primary
alcohols with conversion to the L-cysteine series. (c)
Deprotection of the amine and S→N transfer of the acyl
15 group.

This process is characterized in that it comprises the
following stages (i) of activation of the carboxyl
functional group of N-Boc-L-serine (1) by N-
20 hydroxysuccinimide in DMF in the presence of DCC; then
(ii) of *in situ* condensation of the active ester formed
(1') with ethanolamine (2) to provide the compound N-
(N-Boc-L-seryl)-2-aminoethanol (3); then (iii) of
treatment according to a Mitsunobu reaction, modified
25 by R.P. Volante (*Tetrahedron Lett.*, 1981, 22, 3119-
3122), of N-(N-Boc-L-seryl)-2-aminoethanol with
triphenylphosphine and diisopropyl azodicarboxylate in
the presence of thioacetic acid in tetrahydrofuran
(THF) to provide the compound N-(N-Boc-S-acetyl-L-
30 cysteinyl)-S-acetylcysteamine (4). Thus, the fact of
converting the alcohol of the L-serine into thioester,

while retaining the configuration of the asymmetric carbon, made possible conversion to the L-cysteine series; then (iv) of deprotection of N-(N-Boc-S-acetyl-L-cysteinyl)-S-acetylcysteamine with TFA; conventional
 5 deprotection of the N-Boc of 4 with TFA does not make it possible to isolate the corresponding amine formed 5, which is unstable under our operating conditions, but it makes it possible to synthesize the compound I-152 by an intramolecular S→N transfer reaction of
 10 the acetyl group of 5 via the corresponding thiazoline 6 (scheme 3). Such transfers, in particular on S-acetylcysteamine, have already been observed and studied (R.E. Barnett et al., and the references cited, *J. Amer. Chem. Soc.*, 1969, 91, 2358-2369). These
 15 authors show that the mechanism of transfer involves, under some pH conditions, the formation of an intermediate thiazoline which is subsequently hydrolyzed to generate the N-acetylcysteamine. We find that the formation of I-152 involves the same mechanism since we have isolated and identified the cyclic
 20 intermediate 6 which results from the N-deprotection of 4 via 5 (scheme 3).



25 Scheme 3: Formation of I-152 by an intramolecular S→N transfer reaction of the acetyl group of 5 via the corresponding thiazoline 6.

The S→N transfer reaction of the S-acyl on the cysteine residue makes it possible to obtain the

compound I-152 under the reaction conditions indicated.

09580291 112701

The present invention also relates to a process for the preparation of the compound of general formula I in which R and R' are methyl groups ($-\text{CH}_3$) and R \sim acyl groups; the preparation is carried out by S-acylation of the compound I-152 in solution in pyridine in the presence of an anhydride R_2O or of an acid chloride R-Cl , characterized in that R is chosen from the CO-R^1 group in which R^1 is a linear or branched $\text{C}_1\text{-C}_7$ alkyl radical or an aryl group which is unsubstituted or substituted by one or more halogen atoms. Thus, the preparation of the compound I-176 is carried out by S-acylation of the compound I-152, in solution in pyridine, with acetic anhydride. The preparation of the compound I-177 is carried out by S-acylation of the compound I-152, in solution in pyridine, with isobutyryl chloride. The preparation of the compound I-178 is carried out by S-acylation of the compound I-152, in solution in pyridine, with pivaloyl chloride.

More generally, it is an object of the present invention to provide a process for the preparation of acylated analogues of the compound I-152 or of its derivatives (scheme 4) by using method B of the first way of preparing the compound according to the invention described in scheme 1, route 1. This process comprises the stages of:

- a) protection of N-acetyl-L-cysteine or N-isobutyryl-L-cysteine to provide N-acetyl-S-trityl-L-cysteine (7) and N-isobutyryl-S-trityl-L-cysteine (13) respectively;
- b) various couplings of (7) or (13) with S-acylcysteamine hydrochlorides to provide various corresponding pseudopeptides. Mention should be made, among these, of the compounds 10, 11 and 12, obtained from 7, and the compounds 14, 15, 16 and 17, obtained from 13.

14, 15, 16 and 17 are carried out to give the corresponding thiol compounds I-203, I-208, I-214 and I-219. These compounds can be subjected to a stage:


- 5 d) of S-acylation to provide the compounds described above I-204, I-205, I-206, I-207, I-209, I-210, I-211, I-215, I-216, I-217 and I-218.

Thus, the S-acylation reaction of I-203 makes it possible to obtain the compounds I-204, I-205, I-206
10 and I-207. More particularly, the S-acetylation reaction of I-203 provides I-204, the S-isobutyrylation reaction of I-203 provides I-205, the S-pivaloylation reaction of I-203 provides I-206 and the S-benzoylation reaction of I-203 provides I-207.

15 Thus, the S-acylation reaction of I-208 makes it possible to obtain the compounds I-209, I-210 and I-211. More particularly, the S-acetylation reaction of I-208 provides I-209, the S-isobutyrylation reaction of
20 I-208 provides I-210 and the S-benzoylation reaction of I-208 provides I-211.

Thus, the S-acylation reaction of I-214 makes it possible to obtain the compounds I-215, I-216, I-217
25 and I-218. More particularly, the S-acetylation reaction of I-214 provides I-215, the S-isobutyrylation reaction of I-214 provides I-216, the S-pivaloylation reaction of I-214 provides I-217 and the S-benzoylation reaction of I-214 provides I-218.

30 Thus, the S-acylation reaction of I-219 makes it possible to obtain the compounds I-220, I-221, I-222 and I-223. More particularly, the S-acetylation reaction of I-219 provides I-220, the S-isobutyrylation
35 reaction of I-219 provides I-221, the S-pivaloylation reaction of I-219 provides I-222 and the S-benzoylation reaction of I-219 provides I-223.




Scheme 4: Preparation of acylated analogues of I-152 or of its derivatives by using method B described in scheme 1, route 1.

5

As regards the compounds of the invention in the thiazolidine form, the latter are preferably obtained by coupling N-acyl-S-trityl-L-cysteine with thiazolidine according to method A described in scheme 1, route 1. The invention relates more particularly to the compounds I-212 and I-213 which can be obtained by the process described in scheme 5. In this case, N-acetyl-S-trityl-L-cysteine (7) was coupled according to

10

method A, scheme 1: route 1) with thiazolidine to form the compound 18. The S-detritylation of the latter according to the protocol described above, in particular for the preparation of I-152, makes it possible to generate a free thiol known as I-212. The preparation of the compound I-213 is carried out by S-acetylation of I-212. The three coupling products (18, I-212 and I-213) were respectively isolated in the form of a mixture of two conformational isomers. These isomers are due to the presence of the carbonyl of the pseudopeptide bond alpha to the nitrogen atom of the thiazolidine.



Scheme 5: Preparation of N-(N-NAC)-thiazolidine and of its acetylated derivative via method A described in scheme 1, route 1.

All the compounds of the invention exhibit a common characteristic; they are precursors of compounds which are involved in the route for the biosynthesis of glutathione. In other words, these compounds can be used as intermediates which are involved in the route for the biosynthesis of glutathione. It can relate, for example, to a product chosen from the group formed by NAC, MEA and L-cysteine.

The compounds of the invention exhibit an antioxidant activity. Another subject matter of the invention is therefore the use of the compounds as described above

as antioxidant agents; such compounds have a wide range of uses, such as use in the preventive and curative treatment of pathological syndromes for which an oxidative stress and a GSH deficit are observed, uses
5 in cosmetology or uses in the farm-produce industry.

The invention is targeted at providing antioxidant agents for combating oxidative stress and for increasing the intracellular level of glutathione. The
10 compounds of the present invention can be used as medicament, in particular for increasing the intracellular and/or extracellular level of glutathione. The invention also covers the use of a compound according to the invention in the preparation
15 of a medicament intended to increase the intracellular and/or extracellular level of glutathione. The present invention also relates to a pharmaceutical composition, characterized in that it comprises an effective amount of a compound according to the invention and a
20 pharmaceutically acceptable vehicle. The invention also relates to the use of a compound according to the invention in the preparation of a medicament or of a pharmaceutical composition for the treatment and/or prevention of pathologies or disorders related to an
25 intra- and/or extracellular depletion of glutathione.

The pathologies which can form the subject of a prophylaxis or of a treatment by the compounds of the invention are in particular viral infections, bacterial
30 infections, parasitic infections, diseases of the respiratory tract, neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, cancers, diseases of the immune system, diabetes and preferably type I diabetes, ophthalmic pathologies or
35 dermatological diseases.

The invention relates more particularly to the use of a compound as described above in the preparation of a medicament or of a pharmaceutical composition for the

0988291 112701

5 treatment and/or prevention of viral infections; they
are in particular viral infections caused by DNA
viruses and RNA viruses and more particularly by
retrovid viruses, more particularly the human immuno-
deficiency virus (HIV) and preferably the type-1 human
immunodeficiency virus (HIV-1). Infection by the HIV is
responsible for acquired immunodeficiency syndrome
(AIDS), which constitutes a human pathology in which
oxidizing agents play an important role. AIDS has
10 constituted a public health problem in many countries
in the world since 1981, the date at which the disease
was identified for the first time. When AIDS is
declared, death generally follows two to three years
after diagnosis as a result of the collapse of the
15 immune defenses of the patient and of multiple
opportunistic infections. During infection by the HIV,
a decrease in the cell and plasma levels of antioxidant
molecules is observed. This immune disruption,
christened "oxidative stress", is critical for the
20 patient. It seems to play a major role in the
physiopathology of infections by the HIV by enhancing
viral replication, the inflammatory syndrome,
apoptosis, loss in weight of the patients (cachexia)
and poisoning by medicaments. While the mechanisms
25 contributing to this oxidative stress are poorly
understood, it seems probable that the chronic
inflammatory syndrome associated with HIV infections
accentuates it. Likewise, the HIV, via the Tat protein,
seems itself to play a major role. This is because this
30 protein blocks the production and secretion of
manganese superoxide dismutase (MnSOD), an enzyme which
can prevent oxidative stress, and greatly decreases the
activity of glucose-6-phosphate dehydrogenase (G6PD),
an enzyme necessary for the maintenance of glutathione
35 in its reduced form.

In individuals infected by the HIV, thiols and very
particularly GSH are decreased in the plasma and the
peripheral blood mononuclear cells (PBMCs). Attacks

occur both in the blood and in the tissues, since the GSH deficit is found in the bronchoalveolar lavages and in the central nervous system (CNS). These twofold localizations first confirm that the two major targets of HIV, the lymphocytes and the macrophages, are affected and, secondly, illustrate the scale of the deficit. This can probably explain, at the very least in part, the results published by L.A. Herzenberg et al. (*Proc. Natl. Acad. Sci.*, 1997, 94, 1967-1972). These authors show the existence of a direct connection between patient survival and the GSH level.

Current antiretroviral therapy is based on two families of molecules, reverse transcriptase (RT) inhibitors, (AZT, ddI, nevirapine, and the like) and viral protease inhibitors (indinavir, saquinavir, and the like). They have a degree of *in vivo* activity when they are combined with one another. However, these molecules are incapable of fully reorganizing affected tissues, such as, for example, those affected by inflammatory and oxidative syndromes in the CNS, and have a reduced or zero effectiveness with respect to pathologies associated with infection by the HIV. In view of the major role of GSH in the control of these two syndromes and of its plurality of effects in the physiopathology of HIV infections, numerous alternatives targeted at raising its intracellular level have been envisaged without success as adjuvant therapeutic strategy in recent years.

The unremitting spread of infections by the HIV virus and of the associated opportunistic infections makes it necessary to have available an effective treatment against AIDS and of the associated affected tissues. One of the aims of the present invention is thus to use the compounds corresponding to the general formula (I), preferably the compounds I-152 and/or I-176 and/or I-177 and/or I-178, in the preparation of a medicament or of a pharmaceutical composition for the treatment

and/or prevention of viral infections brought about by the human immunodeficiency virus (HIV) and more particularly the type-1 human immunodeficiency virus (HIV-1). The present invention also provides a pharmaceutical composition for the preventive and curative treatment of AIDS and the associated affected tissues, characterized in that it comprises a therapeutically effective amount of a compound according to the invention and a pharmaceutically acceptable vehicle. The present invention also relates to a product comprising at least one compound according to the invention and at least one reverse transcriptase inhibitor and/or as combination product for a use in antiviral therapy which is simultaneous, separate or spaced out over time. The reverse transcriptase inhibitor is chosen, for example, from 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), (-)-2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3'-dideoxythymidine (d4T) and (-)-2'-deoxy-5-fluoro-3'-thiacytidine (FTC), TIBO, HEPT, TSAO, α -APA, nevirapine, BAHF or phosphonoformic acid (PFA). The viral protease inhibitor is chosen more particularly from indinavir and saquinavir.

It is also within the scope of the invention to use the compounds corresponding to the general formula (I), preferably the compounds I-152 and/or I-176 and/or I-177 and/or I-178, in the preparation of a medicament or of a pharmaceutical composition for the treatment and/or prevention of cardiovascular diseases preferably chosen from the group consisting of arterial hypertension, arteriosclerosis, cerebral ischemia, cardiac ischemia, ventricular arrhythmias, ventricular fibrillation and myocardial infarction. This is because patients affected by arterial hypertension treated with organic nitrates frequently develop resistance to the effects of these drugs. It has been suggested that this tolerance is associated, among factors, with the depletion of thiol groups in the vascular smooth

muscles. It has been demonstrated that metabolic precursors of glutathione, such as NAC, prevent the development of tolerance or at least restore the effects of the organic nitrates (Abrams 1991, Horowitz
5 1991, Bosegaard et al. 1993). The present invention thus proposes to provide novel compounds for preventing the development of tolerance or at least restoring the effects of the organic nitrates used in the treatment of arterial hypertension. Heller et al. (1997) have
10 experimentally demonstrated the action of various reactive oxygen species in the inflammation of the islets of Langerhans and in the destruction of the β cells. It is thus an object of the present invention to provide novel compounds for the treatment and
15 prevention of type-I diabetes (IDDM) (Rabinovitch et al., 1992).

Oxidative stress and GSH deficit are also involved in other pathologies. Thus, in the field of ophthalmology,
20 they can be related to the appearance of cataracts. It is thus within the scope of the invention to use the compounds corresponding to the general formula (I), preferably the compounds I-152 and/or I-176 and/or I-177 and/or I-178, in the preparation of a medicament
25 or of a pharmaceutical composition for the treatment and/or prevention of ophthalmic pathologies, such as the ocular effects of Sjogren's syndrome and cataracts.

It is also within the scope of the invention to use the
30 compounds corresponding to the general formula (I), preferably the compounds I-152 and/or I-176 and/or I-177 and/or I-178, in the preparation of a medicament or of a pharmaceutical composition for the treatment and/or prevention of diseases of the respiratory tract,
35 in particular pulmonary emphysema, idiopathic pulmonary fibrosis, cystic fibrosis, chronic bronchitis, acute bronchitis or adult respiratory distress syndrome.

The invention also relates to the use of a compound as

09980291 112704

described above in the preparation of medicaments intended for the preventive and/or curative treatment of noise-related hearing loss.

- 5 The invention also relates to the use of a compound as described above in the preparation of medicaments intended for the treatment of poisoning related to the oral or parenteral administration, as or not as an overdose, of substances preferably chosen from the
- 10 group consisting of acetaminophen, nitrites, ethanol, acrylonitrile and heavy metals, more particularly gold, silver and mercury.

- The antioxidant properties of the compound of the
- 15 invention recommend it for use in the field of cosmetics. This is because antioxidants are already used in cosmetology to slow down aging. The compounds of the present invention are capable of promoting the rebuilding of the cell content of GSH and of providing
- 20 effective protection against cell damage caused by extrinsic and intrinsic toxic factors; the skin is the site of attack by these factors. The extrinsic factors include, for example, ultraviolet radiation, wind, low humidity, abrasives and strong surface-active agents.
- 25 The intrinsic factors include chronological aging and biochemical modifications of the skin. Whether extrinsic or intrinsic, these factors lead to the appearance of wrinkles and other histological changes associated with aging of the skin. The antiwrinkle
- 30 agents currently known include compounds such as N-acetyl-L-cysteine, retinoids, such as retinoic acid, and alpha-hydroxy acids, such as glycolic acid and lactic acid. It is thus one of the objects of the invention to use the antioxidant properties of the
- 35 compounds according to the invention to (i) prevent, erase and treat wrinkles or fine lines of the skin; and/or (ii) combat cutaneous and/or subcutaneous slackening; and/or (iii) improve the texture of the skin and rekindle the radiance of the skin; and/or (iv)

0560291 112704

remove undesired hairs from the skin; and/or (v) decrease the sizes of the pores of the skin; and/or (vi) permanently deform the hair. As regards the final point, it should be pointed out that organic molecules carrying thiol functional groups, such as the compounds according to the invention, are products having multiple applications. One of these applications is the permanent deformation (curling and straightening) of the hair, which consists, in a first step, in opening the disulfide bonds (S-S) of the cystine units of the keratin using a composition comprising at least one organic compound carrying a thiol functional group which acts as reducing agent (reduction stage), which makes it possible to confer the desired shape on the hair; then, after having rinsed the hair, in reconstituting, in a second step, said disulfide bonds by applying, to the hair, an oxidizing composition (oxidation or fixation stage), so as to fix the hair in the shape which has been given to it. The invention thus relates to a cosmetic composition for the treatment of the skin and/or hair and/or body hairs, characterized in that it comprises a compound according to the invention and a cosmetically acceptable excipient. The invention also relates to a process for the cosmetic treatment of the skin for preventing, erasing and treating wrinkles or fine lines of the skin and/or combating cutaneous and/or subcutaneous slackening and/or improving the texture of the skin and rekindling the radiance of the skin and/or removing undesired hairs from the skin and/or decreasing the sizes of the pores of the skin which comprises the application, to the skin, of a cosmetic composition as described above.

35 The antioxidant properties of the compound of the invention recommend it for use in the farm-produce field. It is thus within the scope of this invention to use the compounds of the invention as antioxidant agents for the preservation of the organoleptic and

nutritional properties of drinks, in particular fruit juices, and food.

Other characteristics and advantages of the present invention will be more clearly demonstrated on reading the following examples: in these examples, reference will be made to the following figures:

Figure 1: Probable decomposition of I-152.

Figure 2: Comparison of the antiviral activities of NAC, of MEA and of I-152 in MDM cultures infected with 10 000 TCID50s of the HIV-1/Ba-L isolate: effect-doses. The results are expressed according to the mean \pm standard deviation of the percentages of inhibition. Viral replication was measured by assaying the reverse transcriptase activity in the culture supernatants.

Figure 3: Cytotoxicity of NAC, MEA and I-152 with respect to MDMs.

Figure 4: Measurement of the RT activity and of the production of protein p25 in the MDM culture supernatants infected with the HIV-1/Ba-L strain and treated with I-152.

Figure 5: Effect of the m.o.i. on the antiviral activity of I-152. The MDMs were infected with 1 000 or 10 000 TCID50s of the HIV-1/Ba-L isolate.

Figure 6: Effects of I-152 on viral replication according to the treatment method: pretreatment 24 hours, treatment 24 hours after infection, treatment 7 days after infection.

Figure 7: Antiviral activity of I-152 in quiescent PBMCs or PBMCs activated with PHA-P, and infected with the HIV-1 LAI strain.

Figure 8: Antiviral activity of I-152 in quiescent PBLs or PBLs activated with PHA-P, then infected with the HIV-1 LAI strain.

Figure 9: Effects of I-152 on the integration of the provirus within the cell genome.

Figure 10: Effects of I-152 on the enzymatic activity of the RT of the HIV-1. The experiments were carried out in triplicate.

00980291 112704
T027T 162660

Figure 11: Assaying of the total intracellular glutathione in quiescent PBMCs, treated 24 hours before with NAC, MEA or I-152.

Figure 12: Antiviral activity of the I-152 derivatives (I-176 is cytotoxic at the dose tested).

Figure 13: Intracellular concentration of GSH in MDMs infected or not infected *in vitro* with the reference strain with macrophage tropism HIV-1/Ba-L, and treated or not treated with the compound I-152.

Figure 14: Effects of the compound I-152 on the intracellular concentration of GSH and the synthesis of TNF- α in MDMs stimulated *in vitro* with a bacterial lipopolysaccharide (LPS; 1 μ g/ml) and IFN- γ (100 IU/ml).

Figure 15: Intracellular concentration of GSH in spleen macrophages after or not after treatment with I-152. The intracellular concentration of GSH in untreated human spleen macrophages is 22 ± 2 μ M.

Figure 16: Intracellular concentration of GSH in spleen macrophages infected or not infected *in vitro* with the reference strain with macrophage tropism HIV-1/Ba-L.

Figure 17: Effects of I-152 on the anti-HIV activity of AZT in MDMs infected with the HIV-1/Ba-L strain.

Table I: Comparison of the antiviral activities of NAC, MEA and I-152 in MDM cultures infected with 10 000 TCID₅₀s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Table II: Effects of the m.o.i. on the antiviral activity of I-152: 50% effective doses.

Table III: Antiviral activity of I-152 in spleen MDMs infected with 10 000 TCID₅₀s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Table IV: Comparison of the antiviral activities of I-152 and its S-acylated analogues in MDM cultures infected with 10 000 TCID₅₀s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

Table V: Comparison of the antiviral activities of I-152 and its variously S-acylated (N-isobutyryl) derivatives in MDM cultures infected with 10 000

TCID50s of the HIV-1/Ba-L isolate: 50, 70 and 90% effective doses.

EXAMPLE 1: SYNTHESIS OF N-(N-ACETYL-L-CYSTEINYL)-S-
5 ACETYLCYSTEAMINE (I-152)

1.1 First route for the synthesis of I-152 using S,N-protected L-cysteine:

10 1.1.1. N-(N-ACETYL-S-TRITYL-L-CYSTEINYL)-S-ACETYLCYSTE-
AMINE (8)

a)- Coupling method involving *in situ* a mixed anhydride

15 A solution comprising 290 mg (0.71 mmol) of N-acetyl-S-trityl-L-cysteine (7, Bachem) and 80 μ l (0.72 mmol) of
of N-methylmorpholine (NMM) in 5 ml of AcOEt is stirred
at -15°C and then 93 μ l (0.71 mmol) of isobutyl
chloroformate are added. After stirring for 15 min and
20 while maintaining the starting temperature, 111.4 mg
(0.71 mmol) of S-acetylcysteamine hydrochloride
(prepared according to T. Wieland and E. Bokelman, Ann.
Chem., 1952, 576, 20-34) and then 80 μ l (0.72 mmol) of
NMM are added. The reaction mixture is maintained at
25 -15°C for 15 min and then, after returning to room
temperature, stirring is continued for 3 h. The NMM
hydrochloride formed is filtered off and washed with
2 x 2.5 ml of AcOEt and the combined organic phases are
evaporated to dryness under vacuum. The coupling
30 product is subsequently isolated from the gum obtained
by flash chromatography on a silica gel column (eluent:
AcOEt/petroleum ether 30%). 198 mg (Yd = 55%) of the
expected compound are collected. R_f (AcOEt/petroleum
ether, 9:1): 0.41. Crystallizes from an AcOEt/petroleum
35 ether mixture in the form of a colorless powder:
M.p. = 111-113°C. $[\alpha]_D^{20} = +10.5^\circ$ (c 0.8, CHCl₃).
¹H NMR (CDCl₃) δ ppm: 1.90 (s, 3H, NCOCH₃), 2.29 (s, 3H,
SCOCH₃), 2.48 (dd, J = 5.7, 12.9 Hz, 1H, β Ha cys), 2.82
(dd, J = 6.4, 12.9 Hz, 1H, β Hb cys), 2.92-3.01 (m, 2H,

5 MS: (FAB⁺/NBA+K⁺) m/z 545 (M+K)⁺, 507 (M+H)⁺; (FAB⁻/NBA) m/z 505 (M-H)⁻.

Calc. %: C 66.40 H 5.93 N 5.53

10

15

A solution comprising 1.5 g (3.70 mmol) of **7** and 410 μ l (3.73 mmol) of NMM in 30 ml of AcOEt is stirred at -15°C and then 480 μ l (3.70 mmol) of isobutyl chloroformate are added. After stirring for 15 min and while maintaining the starting temperature, 426 mg (3.70 mmol) of N-hydroxysuccinimide are added. The reaction mixture is maintained at -15°C for 15 min and then, after returning to ambient temperature, stirring is continued for 2 h. The NMM hydrochloride formed is filtered off and washed with 2 \times 5 ml of AcOEt. The organic phases comprising the O-N-succinimide active ester of **7** are combined and stirred at -15°C. 575 mg (3.70 mmol) of S-acetylcysteamine hydrochloride and 410 μ l (3.73 mmol) of NMM are then successively added to the solution. The reaction mixture is maintained at -15°C for 15 min and then, after returning to ambient temperature, stirring is continued for 12 h. The solution is subsequently diluted with 300 ml of AcOEt, washed (water, 30 ml; ice-cold saturated sodium bicarbonate, 30 ml; water, 30 ml; ice-cold 0.1N citric acid, 30 ml; water, 3 \times 30 ml), dried over sodium sulfate, filtered and evaporated to dryness under vacuum. The residue obtained is subsequently purified as above to give, with a yield of 70% (1.31 g) and with entirely the same physicochemical criteria, the coupling product **8** described above.

1.1.2. N-(N-ACETYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-152)

5 A saturated solution, with the exclusion of light, of
1.26 g (2.49 mmol) of **8** in 20 ml of MeOH and 1.5 ml of
CHCl₃ is stirred at ambient temperature and a mixture,
also with the exclusion of light, comprising 449 mg
(2.64 mmol) of silver nitrate and 213 μ l (2.64 mmol) of
pyridine in 13 ml of MeOH, is added. There is
10 instantaneously formation of a precipitate of the
corresponding silver sulfide **9**. At the end of the
addition, stirring is halted and the reaction mixture
is left overnight at ambient temperature. The
precipitate is subsequently filtered off and washed
15 with MeOH (2 \times 10 ml) and then with CHCl₃ (2 \times 10 ml).

An analytical sample of **9** is withdrawn and is then
dried under vacuum with the exclusion of light.

Analysis: C₉H₁₅N₂O₃S₂Ag (371)

20 Calc. %: Ag 29.11

Found %: 29.16

The preceding sulfide **9** is suspended in 15 ml of CHCl₃
and stirred at ambient temperature with the exclusion
25 of light and then 400 μ l of concentrated hydrochloric
acid are added. Stirring is continued for 2 h at
ambient temperature and then for 2 min at 30-35°C. The
mixture is then diluted with 70 ml of CHCl₃ and the
silver chloride formed is filtered off and then washed
30 with 3 \times 10 ml of the same solvent. The organic phases
are combined, rapidly washed with ice-cold water
(3 \times 10 ml), dried over sodium sulfate, filtered and
evaporated to dryness under vacuum. A semi-crystalline
paste is collected, which paste crystallizes from an
35 AcOEt/petroleum ether mixture in the form of colorless
microcrystals (368 mg, Yd = 56%). M.p. = 121-122°C.
[α]_D²⁰ = -39.1° (c 0.9, CHCl₃). The other data
(microanalyses and spectra) are in all respects
identical to those described in the second synthetic

0980291-112704

route.

H₂S was also used and leads to the same result.

5 1.2. Second route for the synthesis of I-152 using N-protected L-serine:

1.2.1. N-(N-Boc-L-SERYL)-2-AMINOETHANOL (3)

10 A solution comprising 6.15 g (30 mmol) of N-Boc-L-serine (1, Fluka) and 3.45 g of N-hydroxysuccinimide (30 mmol) in 80 ml of DMF is stirred at 0°C and 6.2 g (30 mmol) of DCC are added. The reaction mixture is maintained at 0°C for 15 min, then it is allowed to
15 return to ambient temperature and stirring is continued for 1 h 30. 2.75 ml (60 mmol) of ethanolamine are subsequently added. After stirring for 12 h, the DCU formed is filtered off and washed with 2 x 15 ml of DMF. The combined organic phases are evaporated to
20 dryness under vacuum. The product is isolated from the residual paste by flash chromatography on a silica gel column (Kieselgel Merck 60, 230-400 mesh; eluent: CH₂Cl₂/MeOH 6%). The expected compound is collected in the form of a gum which crystallizes from an
25 AcOEt/hexane mixture to provide 5.21 g (Yd = 70%) of colorless needles. R_f (CH₂Cl₂/MeOH, 9.3/0.7): 0.23; (CH₂Cl₂/MeOH/AcOH, 9/0.9/0.1): 0.47. M.p. = 74-76°C. [α]_D²⁰ = -2.2° (c 0.9, CHCl₃).

¹H NMR (d₆-DMSO) δ ppm: 1.50 (s, 9H, H t-butyl), 3.18-
30 3.29 (m, 2H, NCH₂CH₂O), 3.45-3.55 (m, 2H, NCH₂CH₂O), 3.57-3.70 (m, 2H, β CH₂ ser), 4.01-4.10 (m, 1H, α H ser), 4.77 (t, J = 5.4 Hz, 1H, OH ser), 4.91 (t, J = 5.7 Hz, 1H, NCH₂CH₂OH), 6.71 (d, J = 8.2 Hz, 1H, NH ser); 7.86 (t, J = 5.5 Hz, 1H, NHCH₂).

35 MS: (FAB⁺/G-T) m/z 745 (3M+H)⁺, 497 (2M+H)⁺, 249 (M+H)⁺.

Analysis: C₁₀H₂₀N₂O₅ (248)

Calc. %: C 48.39 H 8.06 N 11.29

Found %: 8.57 8.08 11.08

09980291 112701

1.2.2. N-(N-Boc-S-ACETYL-L-CYSTEINYL)-2-ACETYLCYSTEAMINE

(4)

+

A solution comprising 2.597 g (9.9 mmol) of triphenylphosphine and 1.95 ml (9.91 mmol) of diisopropyl azodicarboxylate in 15 ml of THF is stirred for 30 min at 0°C (after stirring for 30 s, the formation of an intense precipitate is observed). While retaining this temperature, 1.116 g (4.50 mmol) of **3**, in solution in 6 ml of THF, and then 707 µl (9.91 mmol) of thioacetic acid are successively added. The solution obtained is subsequently allowed to return to ambient temperature and stirring is continued for 12 h. The reaction mixture is then evaporated to dryness under vacuum. The product is isolated from the residual paste by flash chromatography on a silica gel column (eluent: hexane and then AcOEt/petroleum ether 75%). The expected compound is collected in the form of a gum which crystallizes from an AcOEt/petroleum ether mixture in the form of colorless needles (1.21 g, Yd = 74%). R_f (AcOEt/petroleum ether, 4/6): 0.35. M.p. = 111-113°C. $[\alpha]_D^{20} = -13.9^\circ$ (c 0.86, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.45 (s, 9H, H t-butyl), 2.36, 2.38 (2s, 2 × 3H, 2 × SCOCH₃), 2.99-3.07 (m, 2H, NCH₂CH₂S), 3.19 (dd, J = 7.8, 14.3 Hz, 1H, β Ha cys), 3.34 (dd, J = 4.5, 14.3 Hz, 1H, β Hb cys), 3.40-3.50 (m, 2H, NCH₂CH₂S), 4.19-4.34 (m, 1H, α H cys), 5.25 (d, J = 7.1 Hz, 1H, NH cys), 6.69 (t, J = 5.2 Hz, 1H, NHCH₂).

MS: (FAB⁺/NBA) m/z 729 (2M+H)⁺, 365 (M+H)⁺.

Analysis: C₁₄H₂₄N₂O₅S₂ (364)

Calc. %: C 46.15 H 6.59 N 7.69

Found %: 46.45 6.51 7.47

1.2.3. N-(N-ACETYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-152)

35

A solution comprising 500 mg (1.37 mmol) of **4** in 5 ml of CH₂Cl₂ is stirred under argon at 0°C and then 1 ml (13.07 mmol) of TFA is added. The solution is

09580291 112701

subsequently allowed to return to ambient temperature and stirring is continued for 7 h. At this stage, the reaction, monitored by TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9.4/0.6), shows the disappearance of the starting compound (R_f : 0.75) and the appearance of two, more polar, spots (R_f : 0.5 and 0.16). The reaction mixture is evaporated to dryness under vacuum (temperature of the water bath: $<40^\circ\text{C}$).

Further monitoring by TLC of the gum obtained indicates that the preceding major spot at R_f : 0.16 has become a minor spot to the advantage of that at R_f : 0.5. The appearance of a third spot, of less importance, at R_f : 0.4 is also recorded. At this stage, we carried out flash chromatography on an aliquot of the gum (20 mg) in order to identify the compounds present in order to elucidate this phenomenon:

- The product of R_f : 0.5 is isolated with a mixture of eluents consisting of $\text{CH}_2\text{Cl}_2/\text{Et}_2\text{O}$ (5/5). The study of its spectra (^1H NMR and MS) unambiguously shows that it is N-(2-methyl- Δ^2 -thiazoliny-4(R)-carbonyl)-S-acetylcysteamine 6:

^1H NMR (CDCl_3) δ ppm: 2.32 (s, 3H, SCOCH_3), 2.39 (d, J = 1.3 Hz, 3H, 2- CH_3 thiazoline), 3.05 (app. t, J = 6.4 Hz, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.36-3.60 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.69 (dd, J = 10.2 and 11.4 Hz, 1H, 5- H thiazoline), 3.85 (dd, J = 7.2 and 11.4 Hz, 1H, 5'- H thiazoline), 5.08 (ddd, J = 1.3, 7.2 and 10.2 Hz, 1H, 4- H thiazoline), 7.45-7.58 (m, 1H, NHCH_2).

MS: ($\text{FAB}^+/\text{G-T}$) m/z 493 ($2\text{M}+\text{H}$) $^+$, 247 ($\text{M}+\text{H}$) $^+$.

- The intermediate compound (R_f :0.4) is isolated by increasing the polarity of the elution solvent ($\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9.5/0.5). The study of its spectra (^1H NMR and MS) shows that it is I-152. Its physicochemical data are reported at the end of this description.

- Continuing the chromatographic separation with more polar eluents ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 5-20%) did not make it possible to obtain the product of R_f : 0.16. This compound, which is the first formed in the reaction for

the deprotection of the terminal amine functional group of the starting N-Boc, can only be N-(S-acetyl-L-cysteinyl)-S-acetylcysteamine trifluoroacetate **5**.

* All the tests carried out and monitored by TLC showed us, under our operating conditions (time necessary for the complete consumption of the starting material, temperature and pH of the reaction medium), that **5**, which is the first formed during deprotection of the N-Boc by TFA, generates the cyclic intermediate **6**, which is subsequently slowly hydrolyzed to give I-152.

Thus, after these various observations, the remaining gum obtained after evaporation of the crude reaction mixture was dissolved in 150 ml of CH₂Cl₂, and then 5 ml of water were added at ambient temperature and with vigorous stirring. After stirring for 6 h, monitoring by TLC shows only a single spot corresponding to the desired product. The organic phase is separated by settling and the residual water is extracted with CH₂Cl₂ (3 × 10 ml). The organic phases are subsequently combined, dried over sodium sulfate, filtered and evaporated to dryness under vacuum. The expected compound is collected in the form of a semi-crystalline paste. R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.4. Crystallizes from an AcOEt/petroleum ether mixture in the form of colorless microcrystals (245 mg, Yd = ≥67%). M.p. = 122-124°C. [α]_D²⁰ = -40° (c 0.87, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.60 (dd, J = 7.6 and 10.3 Hz, 1H, SH), 2.07 (s, 3H, NCOCH₃), 2.36 (s, 3H, SCOCH₃), 2.70 (ddd, J = 6.5, 10.3 and 13.9 Hz, 1H, β Ha cys), 3.03 (t, J = 6.3 Hz, 2H, NCH₂CH₂S), 3.06 (ddd, J = 4.3, 7.6 and 13.9 Hz, 1H, β Hb cys), 3.46 (td, J = 6.0 and 6.3 Hz, 2H, NCH₂CH₂S), 4.59 (ddd, J = 4.3, 6.5 and 7.9 Hz, 1H, α H cys), 6.52 (d, J = 7.9 Hz, 1H, NH cys), 6.75-6.90 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 529 (2M+H)⁺, 265 (M+H)⁺.

Analysis: C₉H₁₆N₂O₃S₂ (264)

Calc. %:	C 40.91	H 6.06	N 10.61	S 24.24
Found %:	41.21	6.00	10.91	23.99

EXAMPLE 2: SYNTHESIS OF ACYLATED DERIVATIVES OF N-(N-ACETYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-152) OR OF ITS DERIVATIVES

5

2.1. N-(N,S-BISACETYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-176)

(General method for S-acylation)

- 10 A solution comprising 83 mg (0.31 mmol) of I-152 in
1 ml of pyridine is stirred at 0°C and 90 µl
(0.95 mmol) of acetic anhydride are added. The reaction
mixture is maintained at 0°C for 15 min, then it is
allowed to return to ambient temperature and stirring
15 is continued for 12 h. The solution is subsequently
evaporated to dryness under vacuum and the residue
formed is taken up in 30 ml of CH₂Cl₂. The organic phase
is washed with water (3 × 20 ml), dried over sodium
sulfate, filtered and evaporated to dryness under
20 vacuum. The residual gum is crystallized from AcOEt and
provides 73 mg (Yd = 75%) of the expected compound in
the form of colorless platelets. R_f (CH₂Cl₂/MeOH,
9.5/0.5): 0.46. M.p. = 153-154°C. [α]_D²⁰ = -33.7° (c
0.8, CHCl₃).
- 25 ¹H NMR (CDCl₃) δ ppm: 2.02 (s, 3H, NCOCH₃), 2.37, 2.39
(2s, 2 × 3H, 2 × SCOCH₃), 2.93, 3.12 (m, 2H, NCH₂CH₂S),
3.24 (dd, J = 7.2 and 14.5 Hz, 1H, β Ha cys), 3.31 (dd,
J = 5.2 and 14.5 Hz, 1H) β Hb cys), 3.39-3.49 (m, 2H,
NCH₂CH₂S), 4.54 (ddd, J = 5.3, 7.2 and 7.3 Hz, 1H, α H
30 cys), 6.44 (d, J = 7.3 Hz, 1H, NH cys), 6.83 (t, J =
5.1 Hz, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 613 (2M+H)⁺, 307 (M+H)⁺.

Analysis: C₁₁H₁₈N₂O₄S₂ (306)

Calc. %: C 43.14 H 5.88 N 9.15 S 20.92

35 Found %: 42.95 5.96 8.93 20.64

2.2. N-(N-ACETYL-S-ISOBUTYRYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-177)

The acylation reaction of 85 mg (0.32 mmol) of **I-152** is carried out, according to the general method described above, using 137 μ l (1.30 mmol) of isobutyryl chloride instead of acetic anhydride. The viscous mixture obtained, after evaporation to dryness under vacuum, is subsequently diluted with 30 ml of CH_2Cl_2 . The solution is subsequently washed (water, 10 ml; ice-cold saturated sodium bicarbonate, 10 ml; water, 10 ml; ice-cold 0.1N citric acid, 10 ml; water, 3 \times 10 ml), dried over sodium sulfate, filtered and evaporated to dryness under vacuum. The acylation product is isolated from the gum obtained by flash chromatography on a silica gel column (eluent: CH_2Cl_2 /ether 50%). 60 mg (Yd = 56%) of the expected compound are collected. R_f (CH_2Cl_2 /MeOH, 9.4/0.6): 0.6. Crystallizes from an AcOEt/petroleum ether mixture in the form of colorless platelets. M.p. = 116-118°C. $[\alpha]_D^{20} = -18.4^\circ$ (c 0.87, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.20 (d, $J = 6.9$ Hz, 6H, $\text{C}(\text{CH}_3)_2$, 2.00 (s, 3H, NCOCH_3), 2.37 (s, 3H, SCOCH_3), 2.80 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$, 2.93, 3.12 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.23-3.30 (m, 2H, β CH_2 cys), 3.38-3.49 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 4.46-4.57 (m, 1H, α H cys), 6.42 (d, $J = 7.3$ Hz, 1H, NH cys), 6.80 (t, $J = 5.2$ Hz, 1H, NHCH_2).

MS: (FAB⁺/G-T) m/z 669 (2M+H)⁺, 335 (M+H)⁺.

Analysis: $\text{C}_{13}\text{H}_{22}\text{N}_2\text{O}_4\text{S}_2$ (334)

Calc. %:	C 46.71	H 6.59	N 8.38	S 19.16
Found %:	46.76	6.89	8.24	19.32

2.3. *N-(N-ACETYL-S-PIVALOYL-L-CYSTEINYL)-S-ACETYLCYSTE-AMINE (I-178)*

The acylation reaction of 95 mg (0.36 mmol) of **I-152** is carried out, according to the general method described above, using 176 μ l (1.44 mmol) of pivaloyl chloride instead of acetic anhydride. The viscous mixture obtained, after evaporation to dryness under vacuum, is subsequently diluted with 30 ml of CH_2Cl_2 . The solution is subsequently washed (water, 10 ml; ice-cold saturated sodium bicarbonate, 10 ml; water, 10 ml; ice-

cold 0.1N citric acid, 10 ml; water, 3 x 10 ml), dried over sodium sulfate, filtered and evaporated to dryness under vacuum. The acylation product is isolated from the gum obtained by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 50%). 70 mg (Yd = 56%) of the expected compound are collected. R_f (CH₂Cl₂/ether, 4/6): 0.23. Crystallizes from an AcOEt/petroleum ether mixture in the form of colorless platelets. M.p. = 92-94°C. [α]_D²⁰ = -11.1° (c 1.08, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.25 (s, 9H, C(CH₃)₃), 2.00 (s, 3H, NCOCH₃), 2.37 (s, 3H, SCOCH₃), 2.94, 3.12 (m, 2H, NCH₂CH₂S), 3.25 (d, J = 6.5 Hz, 2H, β CH₂ cys), 3.38-3.49 (m, 2H, NCH₂CH₂S); 4.51 (td, J = 6.5 and 7.3 Hz, 1H, α H cys), 6.42 (d, J = 7.3 Hz, 1H, NH cys), 6.80 (t, J = 5.2 Hz, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 697 (2M+H)⁺, 349 (M+H)⁺.

Analysis: C₁₄H₂₄N₂O₄S₂ (348)

Calc. %: C 48.28 H 6.90 N 8.05 S 18.39

Found %: 48.32 6.95 7.94 18.43

2.4. N-(N-ACETYL-S-TRITYL-L-CYSTEINYL)-S-ISOBUTYRYL-CYSTEAMINE (10)

The coupling reaction of 7 (4.5 mmol) with S-isobutyrylcysteamine hydrochloride [(compound obtained according to the same methods as those described by T. Wieland and E. Bokelman, Ann. Chem., 1952, 576, 20-34; during the syntheses of S-acetylcysteamine hydrochloride and S-benzoylcysteamine hydrochloride) M.p. = 147-148°C] is carried out according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 30%). 10 is collected in the form of a colorless foam with a yield of 80%. R_f (AcOEt/petroleum ether, 8/2): 0.37. [α]_D²⁰ = +10° (c 1.1, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.16 (d, J = 6.9 Hz, 6H, C(CH₃)₂),

1.90 (s, 3H, NCOCH₃), 2.49 (dd, J = 5.7 and 12.9 Hz, 1H, β Ha cys), 2.70 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.79 (dd, J = 6.4 and 12.9 Hz, 1H, β Hb cys), 2.88-3.01 (m, 2H, NCH₂CH₂S), 3.29-3.41 (m, 2H, NCH₂CH₂S), 4.08-4.19 (m, 1H, α H cys), 5.76 (d, J = 7.7 Hz, 1H, NH cys), 6.36 (t, J = 5.5 Hz, 1H, NHCH₂), 7.15-7.35, 7.38-7.52 (2m, 15H, aromatic H).

MS: (FAB⁺/G-T) m/z 535 (M+H)⁺.

Analysis: C₃₀H₃₄N₂O₃S₂ (534)

10 Calc. %: C 67.42 H 6.37 N 5.24
Found %: 67.25 6.58 5.30

2.5. N-(N-ACETYL-L-CYSTEINYL)-S-ISOBUTYRYLCYSTEAMINE (I-188)

15 This compound is obtained by the S-detritylation of 10 (2.38 mmol). The protocol used is the same as that described in example 1 for the synthesis of I-152. After the various treatments, a gum is collected, which
20 gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/MeOH 1.5%). I-188 is isolated in the form of a colorless semicrystalline gum with a yield of 57%.

25 R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.45. [α]_D²⁰ = -26.6° (c 1.09, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.21 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.61 (dd, J = 7.6 and 10.3 Hz, 1H, SH), 2.09 (s, 3H, NCOCH₃), 2.70 (ddd, J = 6.4, 10.3 and 13.8 Hz, 1H, β Ha cys), 2.77 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.99-3.08 (m, 2H, NCH₂CH₂S), 3.09 (ddd, J = 4.1, 7.6 and 13.8 Hz, 1H, β Hb cys), 3.41-3.53 (m, 2H, NCH₂CH₂S), 4.60 (ddd, J = 4.1, 6.4 and 7.5 Hz, 1H, α H cys), 6.48 (d, J = 7.5 Hz, 1H, NH cys), 6.68-6.88 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 585 (2M+H)⁺, 293 (M+H)⁺.

35 Analysis: C₁₁H₂₀N₂O₃S₂ (292)

Calc. %: C 45.20 H 6.85 N 9.59
Found %: 45.31 7.09 9.41

2.6. N-(N,S-BISACETYL-L-CYSTEINYL)-S-ISOBUTYRYL-

CYSTEAMINE (I-189)

The S-acylation of **I-188** (0.32 mmol) with acetic anhydride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 55%). **I-189** is isolated in the form of a gum (Yd = 64%) which, after trituration in hexane, provides a colorless powder. R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.58. M.p. = 115-117°C. [α]_D²⁰ = -20.2° (c 1.04, CHCl₃). ¹H NMR (CDCl₃) δ ppm: 1.20 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 2.02 (s, 3H, NCOCH₃), 2.38 (s, 3H, SCOCH₃), 2.78 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.96-3.06 (m, 2H, NCH₂CH₂S), 3.19-3.36 (m, 2H, CH₂ cys), 3.38-3.48 (m, 2H, NCH₂CH₂S), 4.47-4.60 (m, 1H, α H cys), 6.37 (d, J = 7.1 Hz, 1H, NH cys); 6.70-6.83 (m, 1H, NHCH₂). MS: (FAB⁺/G-T) m/z 669 (2M+H)⁺, 335 (M+H)⁺. Analysis: C₁₃H₂₂N₂O₄S₂ (334)
Calc. %: C 46.71 H 6.59 N 8.38
Found %: 46.81 6.62 8.36

2.7. N-(N-ACETYL-S-ISOBUTYRYL-L-CYSTEINYL)-S-ISOBUTYRYLCYSTEAMINE (I-190)

The S-acylation of **I-188** (0.32 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 50%). **I-190** is isolated in the form of a gum (Yd = 63%) which, after trituration in hexane, provides a colorless powder. R_f (CH₂Cl₂/ether, 3.5/6.5): 0.34. M.p. = 99-100°C. [α]_D²⁰ = -9.1° (c 0.88, CHCl₃). ¹H NMR (CDCl₃) δ ppm: 1.20 (d, J = 6.9 Hz, 12H, C(CH₃)₂),

2.01 (s, 3H, NCOCH₃), 2.78 (hept, J = 6.9 Hz, 2H, CH(CH₃)₂), 2.92-3.10 (m, 2H, NCH₂CH₂S), 3.26 (d, J = 6.4 Hz, 2H, CH₂ cys), 3.37-3.48 (m, 2H, NCH₂CH₂S), 4.46-4.58 (m, 1H, α H cys), 6.38 (d, J = 7.3 Hz, 1H, NH cys), 6.73-6.83 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 725 (2M+H)⁺, 363 (M+H)⁺.

Analysis: C₁₅H₂₆N₂O₄S₂ (362)

Calc. %: C 49.72 H 7.18 N 7.73

Found %: 49.57 7.19 7.68

2.8. N-(N-ACETYL-S-PIVALOYL-L-CYSTEINYL)-S-ISOBUTYRYL-CYSTEAMINE (I-191)

The S-acylation of I-188 (0.32 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum crystallizes from an AcOEt/petroleum ether mixture in colorless needles (Yd = 68%). R_f (CH₂Cl₂/ether, 5/5): 0.27. M.p. = 103-104°C. [α]_D²⁰ = -8.3° (c 0.97, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.20 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.25 (s, 9H, C(CH₃)₃), 2.01 (s, 3H, NCOCH₃), 2.77 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.94-3.08 (m, 2H, NCH₂CH₂S), 3.25 (d, J = 6.4 Hz, 2H, CH₂ cys), 3.37-3.49 (m, 2H, NCH₂CH₂S), 4.44-4.57 (m, 1H, α H cys), 6.35 (d, J = 7.3 Hz, 1H, NH cys), 6.69-6.80 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 753 (2M+H)⁺, 377 (M+H)⁺.

Analysis: C₁₆H₂₈N₂O₄S₂ (376)

Calc. %: C 51.06 H 7.45 N 7.45

Found %: 51.16 7.53 7.44

2.9. N-(N-ACETYL-S-BENZOYL-L-CYSTEINYL)-S-ISOBUTYRYL-CYSTEAMINE (I-192)

The S-acylation of I-188 (0.32 mmol) with benzoyl chloride is carried out according to the general method described in example 2. The reaction mixture is

subsequently treated according to the protocol described for the synthesis **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent:

5 CH_2Cl_2 /ether 35%). **I-192** is isolated in the form of a gum (Yd = 63%) which, after trituration in hexane, provides a colorless powder. R_f (CH_2Cl_2 /ether, 5/5): 0.27. M.p. = 137-138°C. $[\alpha]_D^{20} = +2.8^\circ$ (c 1.08, CHCl_3). ^1H NMR (CDCl_3) δ ppm: 1.18 (d, $J = 6.9$ Hz, 6H, $\text{C}(\text{CH}_3)_2$),
10 2.02 (s, 3H, NCOCH_3), 2.73 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 2.96-3.06 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.39-3.49 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.50 (d, $J = 6.2$ Hz, 2H, CH_2 cys), 4.60-4.72 (m, 1H, α H cys), 6.59 (d, $J = 7.3$ Hz, 1H, NH cys), 6.85-6.97 (m, 1H, NHCH_2), 7.41-7.52, 7.57-7.65
15 and 7.93-8.01 (3m, 5H, aromatic H).

MS: ($\text{FAB}^+/\text{G-T}$) m/z 793 ($2\text{M}+\text{H}$) $^+$, 397 ($\text{M}+\text{H}$) $^+$.

Analysis: $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_4\text{S}_2$ (396)

Calc. %: C 54.55 H 6.06 N 7.07

Found %: 54.89 6.11 7.06

20 **2.10. N-(N-ACETYL-S-TRITYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (11)**

The coupling reaction of **7** (7.4 mmol) with S-pivaloyl-cysteamine hydrochloride [(compound obtained according to the same methods as those described by T. Wieland and E. Bokelman, *Ann. Chem.*, 1952, 576, 20-34, during the syntheses of S-acetylcysteamine hydrochloride and S-benzoylcysteamine hydrochloride) M.p. = 212-213°C] is
25 carried out according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: CH_2Cl_2 /ether 30%). **11** is collected in the form of a
30 colorless foam with a yield of 86%. R_f (AcOEt/petroleum ether, 7/3): 0.5. $[\alpha]_D^{20} = +8.5^\circ$ (c 1.29, CHCl_3).

35 ^1H NMR (CDCl_3) δ ppm: 1.21 (s, 9H, $\text{C}(\text{CH}_3)_3$), 1.90 (s, 3H, NCOCH_3), 2.49 (dd, $J = 5.9$ and 12.9 Hz, 1H, \square Ha cys), 2.78 (dd, $J = 6.5$ and 12.9 Hz, 1H, β Hb cys), 2.88-2.98

(m, 2H, NCH₂CH₂S), 3.28-3.40 (m, 2H, NCH₂CH₂S), 4.06-4.19 (m, 1H, α H cys), 5.77 (d, J = 7.6 Hz, 1H, NH cys), 6.27-6.41 (m, 1H, NHCH₂), 7.16-7.35 and 7.40-7.48 (2m, 15H, aromatic H).

5 MS: (FAB⁺/G-T) m/z 549 (M+H)⁺.

Analysis: C₃₁H₃₆N₂O₃S₂ (548)

Calc. %: C 67.88 H 6.57 N 5.11

Found %: 66.73 6.70 5.17

10 **2.11. N-(N-ACETYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-193)**

This compound is obtained by S-detritylation of 11 (4.57 mmol). The protocol used is the same as that
15 described in example 1 for the synthesis of I-152. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/MeOH 1.5%). I-193 is isolated in the form of a colorless semicrystalline gum with a
20 yield of 60%.

R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.49. [α]_D²⁰ = -20.2° (c 0.94, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.24 (s, 9H, C(CH₃)₃), 1.61 (dd, J = 7.6 and 10.3 Hz, 1H, SH), 2.08 (s, 3H, NCOCH₃),
25 2.70 (ddd, J = 6.4, 10.3 and 13.9 Hz, 1H, β Ha cys), 2.97-3.09 (m, 2H, NCH₂CH₂S), 3.08 (ddd, J = 4.1, 7.6 and 13.9 Hz, 1H, β, Hb cys), 3.40-3.52 (m, 2H, NCH₂CH₂S), 4.60 (ddd, J = 4.1, 6.4 and 7.8 Hz, 1H, α H cys), 6.49 (d, J = 7.8 Hz, 1H, NH cys), 6.69-6.82 (m, 1H, NHCH₂).

30 MS: (FAB⁺/G-T) m/z 613 (2M+H)⁺, 307 (M+H)⁺.

Analysis: C₁₂H₂₂N₂O₃S₂ (306)

Calc. %: C 47.06 H 7.19 N 9.15

Found %: 47.37 7.23 9.22

35 **2.12. N-(N,S-BISACETYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-194)**

The S-acylation of I-193 (0.33 mmol) with acetic anhydride is carried out according to the general

method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 55%). I-194 is isolated in the form of a gum (Yd = 71%) which crystallizes from an AcOEt/petroleum ether mixture in colorless platelets. R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.58. M.p. = 112-114°C. [α]_D²⁰ = -13.8° (c 0.94, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.24 (s, 9H, C(CH₃)₃), 2.03 (s, 3H, NCOCH₃), 2.38 (s, 3H, SCOCH₃), 2.94-3.04 (m, 2H, NCH₂CH₂S), 3.18-3.36 (m, 2H, CH₂ cys), 3.36-3.48 (m, 2H, NCH₂CH₂S), 4.48-4.60 (m, 1H, α H cys), 6.40 (d, J = 7.5 Hz, 1H, NH cys), 6.71-6.83 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 697 (2M+H)⁺, 349 (M+H)⁺.

Analysis: C₁₄H₂₄N₂O₄S₂ (348)

Calc. %: C 48.28 H 6.90 N 8.05

Found %: 48.34 7.00 7.97

2.13. N-(N-ACETYL-S-ISOBUTYRYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-195)

The S-acylation of I-193 (0.32 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum, after triturations from hexane, provides a colorless powder which is homogeneous by TLC (Yd = 56%). R_f (CH₂Cl₂/ether, 3.5/6.5): 0.46. M.p. = 101-102°C. [α]_D²⁰ = -5.7° (c 1.05, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.20 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.25 (s, 9H, C(CH₃)₃), 2.01 (s, 3H, NCOCH₃), 2.79 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.90-3.08 (m, 2H, NCH₂CH₂S), 3.25 (d, J = 6.3 Hz, CH₂ cys), 3.35-3.47 (m, 2H, NCH₂CH₂S), 4.46-4.58 (m, 1H, α H cys), 6.38 (d, J = 7.1 Hz, 1H, NH cys), 6.71-6.81 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 753 (2M+H)⁺, 377 (M+H)⁺.

Analysis: C₁₆H₂₈N₂O₄S₂ (376)

Calc. %: C 51.06 H 7.45 N 7.45

Found %: 51.20 7.49 7.46

5

2.14. N-(N-ACETYL-S-PIVALOYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-196)

10 The S-acylation of I-193 (0.34 mmol) with pivaloyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum, after

15 triturations in hexane, provides a colorless powder (Yd = 66%). R_f (CH₂Cl₂/ether, 5/5): 0.36. Crystallizes from an AcOEt/petroleum ether mixture in the form of colorless microcrystals. M.p. = 109-111°C. [α]_D²⁰ = -4.4° (c 0.91, CHCl₃).

20 ¹H NMR (CDCl₃) δ ppm: 1.24 (s, 18H, C(CH₃)₃), 2.00 (s, 3H, NCOCH₃), 2.90-3.08 (m, 2H, NCH₂CH₂S), 3.24 (d, J = 6.4 Hz, 2H, CH₂ cys), 3.36-3.47 (m, 2H, NCH₂CH₂S), 4.44-4.57 (m, 1H, α H cys), 6.38 (d, J = 7.4 Hz, 1H, NH cys), 6.68-6.88 (m, 1H, NHCH₂).

25 MS: (FAB⁺/G-T) m/z 781 (2M+H)⁺, 391 (M+H)⁺.

Analysis: C₁₇H₃₀N₂O₄S₂ (390)

Calc. %: C 52.31 H 7.69 N 7.18

Found %: 52.47 7.70 7.14

30 **2.15. N-(N-ACETYL-S-BENZOYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-197)**

The S-acylation of I-193 (0.34 mmol) with benzoyl chloride is carried out according to the general method

35 described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent:

CH₂Cl₂/ether 35%). **I-197** is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 66%). R_f (CH₂Cl₂/ether, 5/5): 0.33. M.p. = 133-134°C. [α]_D²⁰ = +5.10° (c 0.98, CHCl₃).

5 ¹H NMR (CDCl₃) δ ppm: 1.21 (s, 9H, C(CH₃)₃); 2.01 (s, 3H, NCOCH₃), 2.90-3.08 (m, 2H, NCH₂CH₂S), 3.33-3.52 (m, 4H, NCH₂CH₂S, CH₂ cys), 4.64-4.77 (m, 1H, α H cys), 6.76 (d, J = 7.4 Hz, 1H, NH cys), 7.06-7.22 (m, 1H, NHCH₂), 7.40-7.50, 7.55-7.63, 7.91-8.0 (3m, 5H, aromatic H).

10 MS: (FAB⁺/G-T) m/z 821 (2M+H)⁺, 411 (M+H)⁺.

Analysis: C₁₉H₂₆N₂O₄S₂ (410)

Calc. %: C 55.61 H 6.34 N 6.83

Found %: 55.29 6.35 6.75

15 **2.16. N-(N-ACETYL-S-TRITYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (12)**

The coupling reaction of **7** (7.41 mmol) is carried out according to Method B described in the first synthetic route (example 1): S-acetylcysteamine hydrochloride was replaced by S-benzoylcysteamine hydrochloride (T. Wieland and E. Bokelman, Ann. Chem., 1952, 576, 20-34. After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 15%). **12** is collected in the form of a colorless foam with a yield of 62%. R_f (AcOEt/petroleum ether, 7/3): 0.42. [α]_D²⁰ = +10.8° (c 1.11, CHCl₃).

20 ¹H NMR (CDCl₃) δ ppm: 1.86 (s, 3H, NCOCH₃), 2.47 (dd, J = 5.7 and 13.0 Hz, 1H, β Ha cys), 2.82 (dd, J = 6.4 and 13.0 Hz, 1H, β Hb cys), 3.08-3.27 (m, 2H, NCH₂CH₂S), 3.41-3.53 (m, 2H, NCH₂CH₂S), 4.08-4.21 (m, 1H, α H cys), 5.67 (d, J = 7.7 Hz, 1H, NH cys), 6.34-6.46 (m, 1H, NHCH₂), 7.17-7.32, 7.37-7.45, 7.54-7.61, 7.89-7.96 (4m, 20H, aromatic H).

35 MS: (FAB⁺/G-T) m/z 569 (M+H)⁺.

Analysis: C₃₃H₃₂N₂O₃S₂ (568)

Calc. %: C 69.72 H 5.63 N 4.93

Found %: 68.96 5.62 4.89

**2.17. N-(N-ACETYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE
(I-198)**

5 This compound is obtained by the S-detritylation of **12**
(4.44 mmol). The protocol used is the same as that
described in example 1 for the synthesis of **I-152**.
After the various treatments, a gum is collected, which
gum is purified by flash chromatography on a silica gel
10 column (eluent: AcOEt/petroleum ether 50%). **I-198** is
isolated in the form of a white solid with a yield of
63%. R_f CH₂Cl₂/MeOH, 9.5/0.5): 0.38. M.p. = 128-130°C.
[α]_D²⁰ = -24.7° (c 1.01, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.59 (dd, J = 7.6 and 10.2 Hz, 1H,
15 SH), 2.04 (s, 3H, NCOCH₃), 2.71 (ddd, J = 6.5, 10.2 and
13.8 Hz, 1H, β Ha cys), 3.06 (ddd, J = 4.3, 7.6 and
13.8 Hz, 1H, β Hb cys), 3.20-3.31 (m, 2H, NCH₂CH₂S),
3.52-3.64 (m, 2H, NCH₂CH₂S), 4.61 (ddd, J = 4.3, 6.5 and
7.4 Hz, 1H, α H cys), 6.51 (d, J = 7.4 Hz, 1H, NH cys),
20 6.83-7.00 (m, 1H, NHCH₂), 7.43-7.52, 7.56-7.65, 7.92-
8.00 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 653 (2M+H)⁺, 327 (M+H)⁺.

Analysis: C₁₄H₁₈N₂O₃S₂ (326)

Calc. %: C 51.53 H 5.52 N 8.59

25 Found %: 51.49 5.55 8.60

**2.18. N-(N,S-BISACETYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE
(I-199)**

30 The S-acylation of **I-198** (0.34 mmol) with acetic
anhydride is carried out according to the general
method described in example 2. The reaction mixture is
subsequently treated according to the protocol
described for the synthesis of **I-177**. After the various
35 treatments, a gum is collected, which gum is purified
by flash chromatography on a silica gel column (eluent:
CH₂Cl₂/MeOH 1.5%). **I-199** is isolated in the form of a
gum (Yd = 75%) which crystallizes from AcOEt in
colorless needles. R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.44.

M.p. = 166-168°C. $[\alpha]_D^{20} = -14.3^\circ$ (c 0.98, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.99 (s, 3H, NCOCH₃), 2.32 (s, 3H, SCOH₃), 3.18-3.31 (m, 4H, NCH₂CH₂S, CH₂ cys), 3.48-3.61 (m, 2H, NCH₂CH₂S), 4.49-4.62 (m, 1H, α H cys), 6.38 (d, J = 7.6 Hz, 1H, NH cys), 6.79-6.92 (m, 1H, NHCH₂), 7.42-7.51, 7.55-7.64, 7.93-8.01 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 737 (2M+H)⁺, 369 (M+H)⁺.

Analysis: C₁₆H₂₀N₂O₄S₂ (368)

Calc. %: C 52.17 H 5.43 N 7.61

10 Found %: 52.33 5.45 7.68

2.19. N-(N-ACETYL-S-ISOBUTYRYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-200)

15 The S-acylation of **I-198** (0.30 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various
20 treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 40%). **I-200** is isolated in the form of a gum (Yd = 79%) which crystallizes from an AcOEt/petroleum ether mixture in colorless platelets.
25 R_f (CH₂Cl₂/ether, 3/7): 0.2. M.p. = 135-136°C. $[\alpha]_D^{20} = -6.7^\circ$ (c 1.2, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.17 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.97 (s, 3H, NCOCH₃), 2.75 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 3.19-3.30 (m, 4H, NCH₂CH₂S, CH₂ cys), 3.46-
30 3.62 (m, 2H, NCH₂CH₂S), 4.49-4.61 (m, 1H, α H cys), 6.41 (d, J = 7.4 Hz, 1H, NH cys), 6.85-6.96 (m, 1H, NHCH₂), 7.41-7.52, 7.55-7.64, 7.90-8.02 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 793 (2M+H)⁺, 397 (M+H)⁺.

Analysis: C₁₈H₂₄N₂O₄S₂ (396)

35 Calc. %: C 54.54 H 6.06 N 7.07

Found %: 54.77 6.04 7.07

2.20. N-(N-ACETYL-S-PIVALOYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-201)

The S-acylation of **I-198** (0.30 mmol) with pivaloyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 45%). **I-201** is isolated in the form of a gum (Yd = 83%) which crystallizes from an AcOEt/petroleum ether mixture in colorless platelets. R_f (CH₂Cl₂/ether, 3/7): 0.3. M.p. = 101-103°C. [α]_D²⁰ = -3.8° (c 1.05, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.22 (s, 9H, C(CH₃)₃), 1.96 (s, 3H, NCOCH₃), 3.19-3.30 (m, 4H, NCH₂CH₂S, CH₂ cys), 3.46-3.62 (m, 2H, NCH₂CH₂S), 4.47-4.58 (m, 1H, α H cys), 6.38 (d, J = 7.2 Hz, 1H, NH cys), 6.81-6.92 (m, 1H, NHCH₂), 7.42-7.52, 7.55-7.65, 7.90-8.02 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 821 (2M+H)⁺, 411 (M+H)⁺.

Analysis: C₁₉H₂₆N₂O₄S₂ (410)

Calc. %: C 55.61 H 6.34 N 6.83

Found %: 55.73 6.29 6.85

2.21. N-(N-ACETYL-S-BENZOYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-202)

25

The S-acylation of **I-198** (0.30 mmol) with benzoyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/MeOH 1%). **I-202** is isolated in the form of a gum (Yd = 72%) which crystallizes from an AcOEt in colorless platelets. R_f (CH₂Cl₂/MeOH, 9.5/0.5): 0.66. M.p. = 188-190°C. [α]_D²⁰ = +4.1° (c 0.98, CHCl₃).

35

¹H NMR (CDCl₃) δ ppm: 1.99 (s, 3H, NCOCH₃), 3.19-3.28 (m, 2H, NCH₂CH₂S), 3.49 (d, J = 6.1 Hz, 2H, CH₂ cys),

3.52-3.61 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 4.63-4.71 (m, 1H, α H cys),
6.56 (d, $J = 7.2$ Hz, 1H, NH cys), 6.92-7.08 (m, 1H,
NHCH₂), 7.38-7.48, 7.52-7.62, 7.88-7.97 (3m, 10H,
aromatic H).

5 MS: (FAB⁺/G-T) m/z 861 (2M+H)⁺, 431 (M+H)⁺.

Analysis: $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_4\text{S}_2$ (430)

Calc. %: C 58.60 H 5.12 N 6.51

Found %: 58.37 5.10 6.51

10 **2.22. N-ISOBUTYRYL-S-TRITYL-L-CYSTEINE (13)**

This compound was synthesized by adapting, to N-isobutyryl-L-cysteine, the tritylation method described by K.-Y. Zee-Cheng and C.C. Cheng, *J. Med. Chem.*, 1970,
15 13, 414-418. A suspension comprising 4.1 g (21.5 mmol) of N-isobutyryl-L-cysteine [(prepared according to H. Brückner et al., *J. Chromatogr.*, 1989, 476, 73-82), ($[\alpha]_{\text{D}}^{20} = +84^\circ$ (c 1, CHCl_3))], 5.6 g (21.5 mmol) of triphenylmethanol and 16 ml of glacial acetic acid is
20 stirred at ambient temperature. 4.1 ml (32.2 mmol) of BF_3 etherate are added dropwise to the mixture while maintaining the temperature at 20-25°C. After stirring for 3 h, the brown solution obtained is subsequently cooled to 0°C and then 70 ml of an aqueous sodium
25 acetate solution and 140 ml of water are added. At the end of the additions, the reaction mixture sets solid in the form of a gel. This mixture is left overnight at 0°C and then 150 ml of ice-cold water and 120 ml of ether are subsequently added with vigorous stirring.
30 The ethereal phase is separated by settling and the aqueous waste liquors are washed with 4 × 80 ml of ether. The organic phases are combined, washed with 4 × 60 ml of ice-cold water, dried over sodium sulfate, filtered and evaporated to dryness under vacuum. The
35 crude product obtained is purified by washing successively with hexane (5 × 50 ml) to provide **13** in the form of a gum which is homogeneous by TLC with a yield of 81%. R_f ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{AcOH}$, 9.4/0.6/0.07): 0.53. $[\alpha]_{\text{D}}^{20} = +21.4^\circ$ (c 1.12, CHCl_3).

0960291 11201
"T628550"

¹H NMR (CDCl₃) δ ppm: 1.12, 1.14 (2d, J = 2 × 6.9 Hz, 2 × 3H, C(CH₃)₂), 2.24-2.42 (m, 1H, CH(CH₃)₂), 2.64-2.28 (m, 2H, CH₂), 4.31-4.43 (m, 1H, α H), 5.67-6.15 (broad m, 1H, CO₂H), 5.90 (d, J = 7.1 Hz, 1H, NH partially concealing the m at 5.67-6.15), 7.18-7.33, 7.37-7.46 (2m, 15H, aromatic H).

MS: (FAB⁺/G-T) m/z 867 (2M+H)⁺, 431 (M+H)⁺; (FAB⁻/G-T) m/z 865 (2M-H)⁻, 432 (M-H)⁻.

Analysis: C₂₆H₂₇NO₃S₂ (433)

10 Calc. %: C 72.06 H 6.24 N 3.23

Found %: 72.24 6.22 3.28

2.23. N-(N-ISOBUTYRYL-S-TRITYL-L-CYSTEINYL)-S-ACETYL-CYSTEAMINE (14)

15

The coupling reaction of **13** (3.93 mmol) with S-acetylcysteamine hydrochloride is carried out according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 60%). **14** is collected in the form of a colorless foam with a yield of 67%. R_f (AcOEt/petroleum ether, 6/4): 0.5. [α]_D²⁰ = +9.3° (c 0.97, CHCl₃).

25

¹H NMR CDCl₃) δ ppm: 1.10 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 2.18-2.36 (m, 1H, CH(CH₃)₂), 2.29 (s, 3H, SCOCH₃ partially concealing the m at 2.18-2.36), 2.50 (dd, J = 5.6 and 12.8 Hz, 1H, β Ha cys), 2.72 (dd, J = 6.7 and 12.8 Hz, 1H, β Hb cys), 2.88-3.01 (m, 2H, NCH₂CH₂S), 3.29-3.41 (m, 2H, NCH₂CH₂S), 4.06-4.19 (m, 1H, α H cys), 5.82 (d, J = 7.4 Hz, 1H, NH cys), 6.42 (t, J = 5.5 Hz, 1H, NHCH₂), 7.17-7.35, 7.39-7.48 (2m, 15H, aromatic H).

30

MS: (FAB⁺/G-T) m/z 535 (M+H)⁺.

Analysis: C₃₀H₃₄N₂O₃S (534)

35

Calc. %: C 67.42 H 6.37 N 5.24

Found %: 67.05 6.72 5.30

2.24. N-(N-ISOBUTYRYL-L-CYSTEINYL)-S-ACETYLCYSTEAMINE (I-203)

0960291 434

This compound is obtained by the S-detritylation of **14** (2.56 mmol). The protocol used is the same as that described in example 1 for the synthesis of **I-152**.

5 After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 30%). **I-203** is isolated in the form of white solid with a yield of 70%. R_f CH₂Cl₂/ether, 5/5): 0.44. M.p. = 117-120°C. [α]_D²⁰ =
10 -36.5° (c 1.04, CHCl₃).

¹H NMR CDCl₃) δ ppm: 1.19, 1.20 (2d, J = 2 × 6.9 Hz, 2 × 3H, C(CH₃)₂), 1.62 (dd, J = 7.5 and 10.3 Hz, 1H, SH), 2.37 (s, 3H, SCOCH₃), 2.47 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.72 (ddd, J = 6.5, 10.3 and 13.9 Hz, 1H, β
15 Ha cys), 3.00-3.08 (m, 2H, NCH₂CH₂S), 3.06 (ddd, J = 4.2, 7.5 and 13.9 Hz, 1H, β Hb cys), 3.41-3.53 (m, 2H, NCH₂CH₂S), 4.61 (ddd, J = 4.2, 6.5 and 7.4 Hz, 1H, α H cys), 6.46 (d, J = 7.4 Hz, 1H, NH cys), 6.72-6.85 (m, 1H, NHCH₂).

20 MS: (FAB⁺/G-T) m/z 293 (M+H)⁺.

Analysis: C₁₁H₂₀N₂O₃S₂ (292)

Calc. %: C 45.20 H 6.84 N 9.59

Found %: 45.22 7.11 9.69

25 **2.25. N-(N-ISOBUTYRYL-S-ACETYL-L-CYSTEINYL)-S-ACETYL-CYSTEAMINE (I-204)**

The S-acylation of **I-203** (0.34 mmol) with acetic anhydride is carried out according to the general method described in example 2. The reaction mixture is
30 subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 50%). **I-204** is isolated in the
35 semicrystalline form (Yd = 75%), which product, after trituration in hexane provides a colorless powder. R_f (CH₂Cl₂/ether, 2/8): 0.43. M.p. = 125-127°C. [α]_D²⁰ = -22.9° (c 1.05, CHCl₃).

¹H NMR CDCl₃) δ ppm: 1.16 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 2.34-2.47 (m, 1H, CH(CH₃)₂), 2.36, 2.38 (2s, 2 × 3H, 2 × SCOCH₃ partially concealing the m at 2.34-2.47), 2.97-3.06 (m, 2H, NCH₂CH₂S), 3.26-3.32 (m, 2H, CH₂ cys), 3.38-3.48 (m, 2H, NCH₂CH₂S), 4.47-4.58 (m, 1H, α H cys), 6.39 (d, J = 7.3 Hz, 1H, NH cys), 6.80-6.91 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 669 (2M+H)⁺, 335 (M+H)⁺.

Analysis: C₁₃H₂₂N₂O₄S₂ (334)

10	Calc. %:	C 46.71	H 6.59	N 8.38
	Found %:	46.76	6.90	8.35

2.26. N-(N,S-BISISOBUTYRYL-L-CYSTEINYL)-S-ACETYL-CYSTEAMINE (I-205)

15 The S-acylation of I-203 (0.32 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, an oil is collected, which oil is purified by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 70%). I-205 is isolated in the form of a colorless gum (Yd = 56%). R_f (AcOEt/petroleum ether, 4/6): 0.20. [α]_D²⁰ = -17.3° (c 1.1, CHCl₃).

25 ¹H NMR (CDCl₃) δ ppm: 1.16 (d, J = 6.9 Hz, 6H, C(CH₃)₂ of N-i-but.), 1.20, 1.21 (2d, J = 2 × 6.9 Hz, 2 × 3H, C(CH₃)₂ of S-i-but), 2.33-2.46 (m, 1H, CH(CH₃)₂ of N-i-but), 2.36 (s, 3H, SCOCH₃ partially concealing the m at 2.33-2.46); 2.79 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂ of S-i-but), 2.97-3.07 (m, 2H, NCH₂CH₂S), 3.25 (dd, J = 5.0 and 13.8 Hz, 1H, β Ha cys), 3.32 (dd, J = 7.5 and 13.8 H, 1H, β Hb cys), 3.38-3.48 (m, 2H, NCH₂CH₂S), 4.45-4.57 (m, 1H, α H cys), 6.44 (d, J = 7.1 Hz, 1H, NH cys), 6.86-6.97 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 725 (2M+H)⁺, 363 (M+H)⁺.

Analysis: C₁₅H₂₆N₂O₄S₂ (362)

Calc. %:	C 49.72	H 7.18	N 7.73
Found %:	49.87	7.36	7.80

FOXTT 1608660

2.27. N-(N-ISOBUTYRYL-S-PIVALOYL-L-CYSTEINYL)-S-ACETYL-CYSTEAMINE (I-206)

- 5 The S-acylation of **I-203** (0.31 mmol) with pivaloyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various
10 treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 50%). **I-206** is isolated in the semicrystalline form (Yd = 60%), which form, after trituration in hexane, provides a colorless powder. R_f
15 (AcOEt/petroleum ether, 4/6): 0.3. M.p. = 101-103°C. [α]_D²⁰ = -19.3° (c 1.09, CHCl₃).
¹H NMR (CDCl₃) δ ppm: 1.15 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.24 (s, 9H, C(CH₃)₃), 2.30-2.45 (m, 1H, CH(CH₃)₂), 2.36 (s, 3H, SCOCH₃ partially concealing the m at 2.30-
20 2.45), 2.96-3.07 (m, 2H, NCH₂CH₂S), 3.23 (dd, J = 5.3 and 13.8 Hz, 1H, β Ha cys), 3.30 (dd, J = 6.9 and 13.8 Hz, 1H, β Hb cys), 3.37-3.49 (m, 2H, NCH₂CH₂S), 4.44-4.57 (m, 1H, α H cys), 6.44 (d, J = 7.1 Hz, 1H, NH cys), 6.85-6.98 (m, 1H, NHCH₂).
25 MS: (FAB⁺/G-T) m/z 753 (2M+H)⁺, 377 (M+H)⁺.
Analysis: C₁₆H₂₈N₂O₄S₂ (376)
Calc. %: C 51.06 H 7.45 N 7.45
Found %: 50.98 7.72 7.54

30 **2.28. N-(N-ISOBUTYRYL-S-BENZOYL-L-CYSTEINYL)-S-ACETYL-CYSTEAMINE (I-207)**

- The S-acylation of **I-203** (0.31 mmol) with benzoyl chloride is carried out according to the general method
35 described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent:

AcOEt/petroleum ether 75%). **I-207** is isolated in the form of a colorless solid (Yd = 55%) which crystallizes from ether in colorless microcrystals. R_f (CH₂Cl₂/ether, 7.5/2.5): 0.45. M.p. = 135-137°C. $[\alpha]_D^{20} = +3.5^\circ$ (c 1.16, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.12, 1.14 (2d, J = 2 \times 6.9 Hz, 2 \times 3H, C(CH₃)₂), 2.30-2.47 (m, 1H, CH(CH₃)₂), 2.33 (s, 3H, SCOCH₃ partially concealing the m at 2.30-2.47), 2.98-3.07 (m, 2H, NCH₂CH₂S), 3.40-3.58 (m, 4H, CH₂ cys, NCH₂CH₂S), 4.59-4.70 (m, 1H, α H cys), 6.59 (d, J = 7.1 Hz, 1H, NH cys), 6.93-7.04 (m, 1H, NHCH₂), 7.41-7.53, 7.57-7.61, 7.92-8.01 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 793 (2M+H)⁺, 397 (M+H)⁺.

Analysis: C₁₈H₂₄N₂O₄S₂ (396)

15 Calc. %: C 54.54 H 6.06 N 7.07

Found %: 54.51 6.20 7.07

2.29. N-(N-ISOBUTYRYL-S-TRITYL-L-CYSTEINYL)-S-ISOBUTYRYLCYSTEAMINE (15)

20

The coupling reaction of **13** (3.93 mmol) with S-isobutyrylcyteamine hydrochloride is carried out according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 65%). **15** is collected in the form of a colorless foam with a yield of 75%. R_f (AcOEt/petroleum ether, 5/5): 0.6. $[\alpha]_D^{20} = +7.9^\circ$ (c 1.27, CHCl₃).

30 ¹H NMR (CDCl₃) δ ppm: 1.107, 1.110, 1.159, 1.162 (4d, J = 4 \times 6.9 Hz, 4 \times 3H, 2 \times C(CH₃)₂, 2.17-2.32 (m, 1H, CH(CH₃)₂ of N-i-but), 2.51 (dd, J = 5.7 and 12.8 Hz, 1H, β Ha cys), 2.63-2.79 (m, 1H, CH(CH₃)₂ of S-i-but), 2.72 (dd, J = 6.8 and 12.8 Hz, 1H, β Hb cys partially concealing the m at 2.63-2.79), 2.88-2.98 (m, 2H, NCH₂CH₂S), 3.29-3.40 (m, 2H, NCH₂CH₂S), 4.07-4.19 (m, 1H, α H cys), 5.81 (d, J = 7.3 Hz, 1H, NH cys), 6.32-6.43 (m, 1H, NHCH₂), 7.18-7.35, 7.39-7.47 (2m, 15H, aromatic H).

MS: (FAB⁺/G-T) m/z 563 (M+H)⁺.

Analysis: C₃₂H₃₈N₂O₃S₂ (562)

Calc. %: C 68.33 H 6.76 N 4.98

Found %: 68.27 6.71 4.88

5

2.30. N-(N-ISOBUTYRYL-L-CYSTEINYL)-S-ISOBUTYRYLCYSTE-AMINE (I-208)

10 This compound is obtained by the S-detritylation of **15** (2.75 mmol). The protocol used is the same as that described in example 1 for the synthesis of **I-152**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 25%). **I-208** is isolated in 15 the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 69%). R_f (CH₂Cl₂/ether, 5/5): 0.39. M.p. = 125-127°C. [α]_D²⁰ = -25.7° (c 1.05, CHCl₃).

1H NMR (CDCl₃) δ ppm: 1.19, 1.20 (2d, J = 2 × 6.9 Hz, 2 20 × 6H, 2 × C(CH₃)₂), 1.62 (dd, J = 7.5 and 10.3 Hz, 1H, SH), 2.41-2.54 (m, 1H, CH(CH₃)₂ of N-i-but), 2.70-2.84 (m, 1H, CH(CH₃)₂ of S-i-but), 2.72 (ddd, J = 6.5, 10.3 and 13.7 Hz, 1H, β Ha cys partially concealing the m at 2.70-2.84), 2.98-3.14 (m, 3H, β Hb cys, NCH₂CH₂S), 3.42- 25 3.53 (m, 2H, NCH₂CH₂S), 4.54-4.66 (m, 1H, α H cys), 5.81 (d, J = 7.4 Hz, 1H, NH cys), 6.74-6.85 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 641 (2M+H)⁺, 321 (M+H)⁺.

Analysis: C₁₃H₂₄N₂O₃S₂ (320)

Calc. %: C 48.75 H 7.50 N 8.75

30 Found %: 48.45 7.82 8.75

2.31. N-(N-ISOBUTYRYL-S-ACETYL-L-CYSTEINYL)-S-ISOBUTYRYLCYSTEAMINE (I-209)

35 The S-acylation of **I-208** (0.28 mmol) with acetic anhydride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various

05980291 1104
10/22/77 16208650

treatments, a gum is collected, which gum, after triturations in hexane, provides a colorless powder which is homogeneous by TLC with a yield of 80%. R_f (CH_2Cl_2 /

5 ether, 5/5): 0.55. M.p. = 100-102°C. $[\alpha]_D^{20} = -22.9^\circ$ (c 0.92, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.15, 1.20 (2d, $J = 2 \times 6.9$ Hz, $2 \times 6\text{H}$, $2 \times \text{C}(\text{CH}_3)_2$), 2.34-2.47 (m, 1H, $\text{CH}(\text{CH}_3)_2$ of N-*i*-but), 2.37 (s, 3H, SCOCCH_3 partially concealing the m at
10 2.34-2.47), 2.69-2.82 (m, 1H, $\text{CH}(\text{CH}_3)_2$ of S-*i*-but), 2.95-3.05 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.26-3.32 (m, 2H, CH_2 cys), 3.37-3.47 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 4.47-4.59 (m, 1H, α H cys), 6.39 (d, $J = 7.1$ Hz, 1H, NH cys), 6.79-6.90 (m, 1H, NHCH_2).

15 MS: (FAB⁺/G-T) m/z 725 ($2\text{M}+\text{H}$)⁺, 363 ($\text{M}+\text{H}$)⁺.

Analysis: $\text{C}_{15}\text{H}_{26}\text{N}_2\text{O}_4\text{S}_2$ (362)

Calc. %: C 49.72 H 7.18 N 7.73

Found %: 49.47 7.41 7.70

20 **2.31. N-(N,S-BISISOBUTYRYL-L-CYSTEINYL)-S-ISOBUTYRYL-CYSTEAMINE (I-210)**

The S-acylation of **I-208** (0.28 mmol) with isobutyryl chloride is carried out according to the general method
25 described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent:
30 CH_2Cl_2 /ether 25%). **I-210** is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 63%). R_f (CH_2Cl_2 /ether, 5/5): 0.68. M.p. = 94-96°C. $[\alpha]_D^{20} = -11^\circ$ (c 0.91, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.154, 1.158, 1.199, 1.202 (4d, $J = 4 \times 6.9$ Hz, $2 \times 3\text{H}$, $2 \times 6\text{H}$, $3 \times \text{C}(\text{CH}_3)_2$), 2.32-2.46 (m, 1H, $\text{CH}(\text{CH}_3)_2$ of N-*i*-but), 2.69-2.86 (m, 2H, $2 \times \text{CH}(\text{CH}_3)_2$ of $2 \times$ S-*i*-but), 2.93-3.07 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.25 (dd, $J = 5.0$ and 14.5 Hz, 1H, β Ha cys), 3.32 (dd, $J = 7.7$ and 14.5 Hz, 1H, β Hb cys), 3.38-3.47 (m, 2H,

MS: (FAB⁺/G-T) *m/z* 781 (2M+H)⁺, 391 (M+H)⁺.

5	Calc. %:	C	52.31	H	7.69	N	7.18
	Found %:		52.02		8.02		7.21

10

¹H NMR (CDCl₃) δ ppm: 1.12, 1.15, 1.18 (3d, J = 3 × 6.9 Hz, 2 × 3H, 1 × 6H, 2 × C(CH₃)₂), 2.36-2.46 (m, 1H, CH(CH₃)₂ of N-*i*-but), 2.68-2.80 (m, 1H, CH(CH₃)₂ of S-*i*-but), 2.95-3.05 (m, 2H, NCH₂CH₂S), 3.40-3.62 (m, 4H, CH₂cys, NCH₂CH₂S), 4.56-4.69 (m, 1H, α H cys), 6.54 (d, J = 7.0 Hz, 1H, NH cys), 6.84-6.95 (m, 1H, NHCH₂), 7.42-7.51, 7.57-7.65, 7.94-8.01 (m, 5H, aromatic H).

Analysis: $C_{20}H_{28}N_2O_4S_2$ (424)

Found %:	56.42	6.79	6.63
----------	-------	------	------

35

The coupling reaction of **13** (3.93 mmol) of S-pivaloylcysteamine hydrochloride is carried out

according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 70%). **16** is collected in the form of a foam which, after trituration in hexane, provides a colorless powder (Yd = 88%). R_f (CH₂Cl₂/ether, 6/4): 0.82. M.p. = 85-88°C. $[\alpha]_D^{20} = +5.9^\circ$ (c 1.02, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.11 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.21 (s, 9H, C(CH₃)₃), 2.20-2.38 (m, 1H, CH(CH₃)₂), 2.51 (dd, J = 5.6 and 12.9 Hz, 1H, β Ha cys), 2.72 (dd, J = 6.7 and 12.9 Hz, 1H, β Hb cys), 2.84-2.96 (m, 2H, NCH₂CH₂S), 3.27-3.39 (m, 2H, NCH₂CH₂S), 4.03-4.17 (m, 1H, α H cys), 5.78 (d, J = 7.4 Hz, 1H, NH cys), 6.22-6.34 (m, 1H, NHCH₂), 7.18-7.35, 7.38-7.48 (2m, 15H, aromatic H).

MS: (FAB⁺/G-T) m/z 577 (M+H)⁺.

Analysis: C₃₃H₄₀N₂O₃S₂ (576)

Calc. %: C 68.75 H 6.94 N 4.86

Found %: 68.49 6.98 4.93

2.34. N-(N-ISOBUTYRYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-214)

This compound is obtained by the S-detritylation of **16** (2.78 mmol). The protocol used is the same as that described in example 1 for the synthesis of **I-152**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 22%). **I-214** is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 70%). R_f (CH₂Cl₂/ether, 5/5): 0.46. M.p. = 120-122°C. $[\alpha]_D^{20} = -25^\circ$ (c 1.04, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.194, 1.198 (2d, J = 2 \times 6.9 Hz, 2 \times 3H, C(CH₃)₂), 1.23 (s, 9H, C(CH₃)₃), 1.61 (dd, J = 7.6 and 10.2 Hz, 1H, SH), 2.47 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.72 (ddd, J = 6.5, 10.2 and 13.8 Hz, 1H, β Ha cys), 2.95-3.13 (m, 3H, β Hb cys, NCH₂CH₂S), 3.40-

T0227-142704 09980291

3.52 (m, 2H, NCH₂CH₂S), 4.54-4.66 (m, 1H, α H cys), 6.49 (d, J = 7.5 Hz, 1H, NH cys), 6.73-6.88 (m, 1H, NHCH₂).

MS: (FAB⁺/G-T) m/z 669 (2M+H)⁺, 335 (M+H)⁺.

Analysis: C₁₄H₂₆N₂O₃S₂ (334)

5 Calc. %: C 50.30 H 7.78 N 8.38

Found %: 50.19 7.92 8.35

2.35. N-(N-ISOBUTYRYL-S-ACETYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-215)

10

The S-acylation of **I-214** (0.27 mmol) with acetic anhydride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum, after triturations in hexane, provides a colorless powder which is homogeneous by TLC with a yield of 80%. R_f (CH₂Cl₂/ether, 6/4): 0.45. M.p. = 112-114°C. [α]_D²⁰ =

20

-18.8° (c 0.9, CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.16 (d, J = 6.9 Hz, 6H, C(CH₃)₂), 1.24 (s, 9H, C(CH₃)₃), 2.31-2.49 (m, 1H, CH(CH₃)₂), 2.37 (s, 3H, SCOCH₃ partially concealing the m at 2.31-2.49), 2.88-3.08 (m, 2H, NCH₂CH₂S), 3.25-3.34 (m, 2H, CH₂ cys), 3.35-3.47 (m, 2H, NCH₂CH₂S), 4.48-4.60 (m, 1H, α H cys), 6.38 (d, J = 7.3 Hz, 1H, NH cys), 6.74-6.89 (m, 1H, NHCH₂).

25

MS: (FAB⁺/G-T) m/z 377 (M+H)⁺.

Analysis: C₁₅H₂₈N₂O₄S₂ (376)

30

Calc. %: C 51.06 H 7.45 N 7.45

Found %: 50.97 7.81 7.47

2.36. N-(N,S-BISISOBUTYRYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-216)

35

The S-acylation of **I-214** (0.26 mmol) with isobutyryl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol

described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 15%). **I-216** is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 78%). R_f (CH₂Cl₂/ether, 6/4): 0.61. M.p. = 105-107°C. [α]_D²⁰ = -12.2° (c 1.07, CHCl₃). ¹H NMR (CDCl₃) δ ppm: 1.154, 1.157, 1.196, 1.201 (4d, J = 4 × 6.9 Hz, 4 × 3H, 2 × C(CH₃)₂), 1.24 (s, 9H, C(CH₃)₃), 2.39 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂ of N-*i*-but), 2.79 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂ of S-*i*-but), 2.87-3.08 (m, 2H, NCH₂CH₂S), 3.25 (dd, J = 5.2 and 14.5 Hz, 1H, β *Ha* cys), 3.32 (dd, J = 7.5 and 14.5 Hz, 1H, β *Hb* cys), 3.37-3.47 (m, 2H, NCH₂CH₂S), 4.46-4.59 (m, 1H, α *H* cys), 6.43 (d, J = 7.0 Hz, 1H, NH cys), 6.81-6.93 (m, 1H, NHCH₂). MS: (FAB⁺/G-T) m/z 809 (2M+H)⁺, 405 (M+H)⁺. Analysis: C₁₈H₃₂N₂O₄S₂ (404)
Calc. %: C 53.47 H 7.92 N 6.93
Found %: 53.33 8.09 6.95

2.37. N-(N-ISOBUTYRYL-S-PIVALOYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-217)

The S-acylation of **I-214** (0.26 mmol) with pivaloyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **I-177**. After the various treatments, a gum is collected, which gum, after triturations in hexane, provides a colorless powder which is homogeneous by TLC with a yield of 55%. R_f (CH₂Cl₂/ether, 6/4): 0.63. M.p. = 106-108°C. [α]_D²⁰ = -10.2° (c 1.18, CHCl₃). ¹H NMR (CDCl₃) δ ppm: 1.151, 1.157 (2d, J = 2 × 6.9 Hz, 2 × 3H, C(CH₃)₂), 1.240, 1.244 (2s, 2 × 9H, 2 × C(CH₃)₃), 2.38 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 2.86-3.07 (m, 2H, NCH₂CH₂S), 3.24 (dd, J = 5.0 and 14.2 Hz, 1H, β *Ha* cys), 3.30 (dd, J = 6.5 and 14.2 Hz, 1H, β *Hb* cys),

3.33-3.48 (m, 2H, NCH₂CH₂S), 4.42-4.54 (m, 1H, α H cys),
6.39 (d, J = 7.0 Hz, 1H, NH cys), 6.74-6.86 (m, 1H,
NHCH₂).

MS: (FAB⁺/G-T) m/z 837 (2M+H)⁺, 419 (M+H)⁺.

5 Analysis: C₁₉H₃₄N₂O₄S₂ (418)

Calc. %: C 54.81 H 8.17 N 6.73

Found %: 54.50 8.27 6.74

10 **2.38. N-(N-ISOBUTYRYL-S-BENZOYL-L-CYSTEINYL)-S-PIVALOYL-CYSTEAMINE (I-218)**

The S-acylation of **I-214** (0.26 mmol) with benzoyl
chloride is carried out according to the general method
described in example 2. The reaction mixture is
subsequently treated according to the protocol
described for the synthesis of **I-177**. After the various
treatments, a gum is collected, which gum is purified
by flash chromatography on a silica gel column (eluent:
CH₂Cl₂/ether 25%). **I-218** is isolated in the form of a
gum which, after trituration in hexane, provides a
colorless powder (Yd = 73%). R_f (CH₂Cl₂/ether, 5/5):
0.57. M.p. = 123-124°C. [α]_D²⁰ = +8.7° (c 0.92, CHCl₃).
¹H NMR (CDCl₃) δ ppm: 1.12, 1.14 (2d, J = 2 × 6.9 Hz,
2 × 3H, C(CH₃)₂), 1.22 (s, 9H, C(CH₃)₃), 2.40 (app. hept,
J = 6.9 Hz, 1H, CH(CH₃)₂), 2.89-3.09 (m, 2H, NCH₂CH₂S),
3.37-3.61 (m, 4H, NCH₂CH₂S, CH₂ cys), 4.57-4.70 (m, 1H,
α H cys), 6.55 (d, J = 7.3 Hz, 1H, NH cys), 6.84-6.94
(m, 1H, NHCH₂), 7.41-7.52, 7.55-7.66, 7.92-8.01 (3m,
5H, aromatic H).

30 MS: (FAB⁺/G-T) m/z 877 (2M+H)⁺, 439 (M+H)⁺.

Analysis: C₂₁H₃₀N₂O₄S₂ (438)

Calc. %: C 57.53 H 6.85 N 6.39

Found %: 57.53 6.89 6.37

35 **2.39. N-(N-ISOBUTYRYL-S-TRITYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (17)**

The coupling reaction of **13** (3.93 mmol) with S-
benzoylcysteamine hydrochloride is carried out

according to method B described in the first synthetic route (example 1). After the various treatments, the expected compound is isolated by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 70%). **17** is collected in the form of a foam which, after trituration in hexane, provides a colorless foam (Yd = 77%). R_f (CH_2Cl_2 /ether, 6/4): 0.76. $[\alpha]_D^{20} = +7.8^\circ$ (c 1.03, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.09 (d, $J = 6.9$ Hz, 6H, $\text{C}(\text{CH}_3)_2$), 2.18-2.31 (m, 1H, $\text{CH}(\text{CH}_3)_2$), 2.51 (dd, $J = 5.6$ and 12.9 Hz, 1H, β Ha cys), 2.74 (dd, $J = 6.7$ and 12.9 Hz, 1H, β Hb cys), 3.07-3.25 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 3.40-3.51 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 4.07-4.19 (m, 1H, α H cys), 5.74 (d, $J = 7.6$ Hz, 1H, NH cys), 6.35-6.45 (m, 1H, NHCH_2), 7.17-7.33, 7.38-7.47, 7.53-7.62, 7.89-7.96 (4m, 20H, aromatic H).

MS: (FAB⁺/G-T) m/z 597 ($\text{M}+\text{H}$)⁺.

Analysis: $\text{C}_{35}\text{H}_{36}\text{N}_2\text{O}_3\text{S}_2$ (596)

Calc. %: C 70.47 H 6.04 N 4.70

Found %: 70.14 6.10 4.79

2.40. *N*-(*N*-ISOBUTYRYL-*L*-CYSTEINYL)-*S*-BENZOYL-CYSTEAMINE (I-219)

This compound is obtained by the S-detritylation of **17** (2.68 mmol). The protocol used is the same as that described in example 1 for the synthesis of **I-152**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH_2Cl_2 /ether 25%). **I-219** is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 58%). R_f (CH_2Cl_2 /ether, 6/4): 0.35. M.p. = 127-130°C. $[\alpha]_D^{20} = -20.8^\circ$ (c 1.06, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.17, 1.18 (2d, $J = 2 \times 6.9$ Hz, $2 \times 3\text{H}$, $\text{C}(\text{CH}_3)_2$), 1.59 (dd, $J = 7.5$ and 10.3 Hz, 1H, SH), 2.44 (app. hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 2.70 (ddd, $J = 6.5$, 10.3 and 13.8 Hz, 1H, β Ha cys), 3.07 (ddd, $J = 4.2$, 7.5 and 13.8 Hz, 1H, β Hb cys), 3.17-3.34 (m, 2H,

NCH₂CH₂S), 3.53-3.64 (m, 2H, NCH₂CH₂S), 4.62 (ddd, J = 4.2, 6.5 and 8.0 Hz, 1H, α H cys), 6.47 (d, J = 8.0 Hz, 1H, NH cys), 6.80-6.91 (m, 1H, NHCH₂), 7.42-7.53, 7.56-7.65, 7.92-8.01 (3m, 5H, aromatic H).

5 MS: (FAB⁺/G-T) m/z 709 (2M+H)⁺, 355 (M+H)⁺.

Analysis: C₁₆H₂₂N₂O₃S₂ (354)

Calc. %: C 54.23 H 6.21 N 7.91

Found %: 54.20 6.18 7.94

10 **2.41. N-(N-ISOBUTYRYL-S-ACETYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-220)**

The S-acylation of I-219 (0.25 mmol) with acetic anhydride is carried out according to the general
15 method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent:
20 CH₂Cl₂/ether 15%). I-220 is isolated in the form of a gum which, after trituration in hexane, provides a colorless powder (Yd = 70%). R_f (CH₂Cl₂/ether, 7.5/2.5): 0.43. M.p. = 174-176°C. [α]_D²⁰ = -17.6° (c 0.91, CHCl₃).
25 ¹H NMR (CDCl₃) δ ppm: 1.13, 1.14 (2d, J = 2 \times 6.9 Hz, 2 \times 3H, C(CH₃)₂), 2.29-2.45 (m, 1H, CH(CH₃)₂), 2.32 (s, 3H, SCOCH₃ partially concealing the m at 2.29-2.45), 3.18-3.38 (m, 4H, NCH₂CH₂S, CH₂ cys), 3.45-3.62 (m, 2H, NCH₂CH₂S), 4.50-4.62 (m, 1H, α H cys), 6.39 (d, J = 7.1 Hz, 1H, NH cys), 6.88-6.98 (m, 1H, NHCH₂), 7.42-
30 7.52, 7.55-7.64, 7.92-8.01 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 793 (2M+H)⁺, 397 (M+H)⁺.

Analysis: C₁₈H₂₄N₂O₄S₂ (396)

Calc. %: C 54.54 H 6.06 N 7.07

Found %: 54.46 6.02 7.08

35

2.42. N-(N,S-BISISOBUTYRYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-221)

The S-acylation of I-219 (0.25 mmol) with isobutyryl

chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum, after triturations in hexane, provides a colorless powder which is homogeneous by TLC with a yield of 86%. R_f (CH_2Cl_2 /ether, 7.5/2.5): 0.42. M.p. = 141-143°C. $[\alpha]_D^{20} = -9^\circ$ (c 1.11, CHCl_3).

^1H NMR (CDCl_3) δ ppm: 1.13, 1.14 (2d, $J = 2 \times 6.9$ Hz, $2 \times 3\text{H}$, $\text{C}(\text{CH}_3)_2$ of N-*i*-but), 1.18 (d, $J = 6.9$ Hz, 6H, $\text{C}(\text{CH}_3)_2$ of S-*i*-but), 2.37 (app. hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$ of N-*i*-but), 2.75 (app. hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$ of S-*i*-but), 3.16-3.38 (m, 4H, CH_2 cys, $\text{NCH}_2\text{CH}_2\text{S}$), 3.42-3.64 (m, 2H, $\text{NCH}_2\text{CH}_2\text{S}$), 4.47-4.58 (m, 1H, α H cys), 6.42 (d, $J = 7.0$ Hz, 1H, NH cys), 6.87-7.01 (m, 1H, NHCH_2), 7.41-7.50, 7.55-7.63, 7.93-8.01 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 849 ($2\text{M}+\text{H}$)⁺, 425 ($\text{M}+\text{H}$)⁺.

Analysis: $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_4\text{S}_2$ (424)

Calc. %: C 56.60 H 6.60 N 6.60

Found %: 56.67 6.62 6.63

2.43. N-(N-ISOBUTYRYL-S-PIVALOYL-L-CYSTEINYL)-S-BENZOYL-CYSTEAMINE (I-222)

The S-acylation of I-219 (0.25 mmol) with pivaloyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH_2Cl_2 /ether 20%). I-222 is isolated in the form of a gum (Yd = 50%) which, after trituration in hexane, provides a colorless powder. R_f (CH_2Cl_2 /ether, 5/5): 0.55. M.p. = 112-114°C. $[\alpha]_D^{20} = +4.6^\circ$ (c 1.08, CHCl_3). ^1H NMR (CDCl_3) δ ppm: 1.12, 1.13 (2d, $J = 2 \times 6.9$ Hz, $2 \times 3\text{H}$, $\text{C}(\text{CH}_3)_2$), 1.22 (s, 9H, $\text{C}(\text{CH}_3)_3$), 2.36 (app. hept, J

= 6.9 Hz, 1H, CH(CH₃)₂), 3.18-3.36 (m, 4H, CH₂ cys, NCH₂CH₂S), 3.45-3.62 (m, 2H, NCH₂CH₂S), 4.48-4.60 (m, 1H, α H cys), 6.48 (d, J = 7.2 Hz, 1H, NH cys), 6.96-7.08 (m, 1H, NHCH₂), 7.40-7.51, 7.54-7.63, 7.92-8.01 (3m, 5H, aromatic H).

MS: (FAB⁺/G-T) m/z 877 (2M+H)⁺, 439 (M+H)⁺.

Analysis: C₂₁H₃₀N₂O₄S₂ (438)

Calc. %: C 57.53 H 6.85 N 6.39

Found %: 57.31 6.86 6.34

2.44. N-(N-ISOBUTYRYL-S-BENZOYL-L-CYSTEINYL)-S-BENZOYLCYSTEAMINE (I-223)

The S-acylation of I-219 (0.26 mmol) with benzoyl chloride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of I-177. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: CH₂Cl₂/ether 20%). I-223 is isolated in the form of a gum (Yd = 84%) which, after trituration in hexane, provides a colorless powder. R_f (CH₂Cl₂/ether, 7:3): 0.41. M.p. = 154-156°C. [α]_D²⁰ = +7.6° (c 0.92; CHCl₃).

¹H NMR (CDCl₃) δ ppm: 1.10, 1.11 (2d, J = 2 × 6.9 Hz, 2 × 3H, C(CH₃)₂), 2.38 (app. hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 3.19-3.28 (m, 2H, NCH₂CH₂S), 3.43-3.64 (m, 4H, CH₂ cys, NCH₂CH₂S), 4.58-4.71 (m, 1H, α H cys), 6.55 (d, J = 7.2 Hz, 1H, NH cys), 6.92-7.01 (m, 1H, NHCH₂), 7.39-7.50, 7.53-7.64, 7.91-7.99 (3m, 10H, aromatic H).

MS: (FAB⁺/G-T) m/z 917 (2M+H)⁺, 459 (M+H)⁺.

Analysis: C₂₃H₂₆N₂O₄S₂ (458)

Calc. %: C 60.26 H 5.68 N 6.11

Found %: 60.22 5.67 6.00

2.45. N-(N-ACETYL-S-TRITYL-L-CYSTEINYL) THIAZOLIDINE (18)

The coupling reaction of 7 (2 mmol) with thiazolidine

is carried out according to method A described in the first synthetic route (example 1). After returning to ambient temperature, stirring is continued for 12 h. The reaction medium is then diluted with 50 ml of AcOEt, then washed (water, 70 ml; ice-cold saturated sodium bicarbonate, 50 ml; water, 2 x 50 ml), dried over sodium sulfate and evaporated to dryness under vacuum. The colorless foam obtained is subsequently purified by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 30%). **18** is isolated in the form of a colorless gum with a yield of 80%. R_f (AcOEt/petroleum ether, 8/2): 0.40. Crystallizes from MeOH in colorless needles. M.p. = 197-198°C. $[\alpha]_D^{20} = +0.86^\circ$ (c 1.16, CHCl₃).

¹H NMR (CDCl₃) δ ppm (isomeric mixture, 5.2/4.8: 1.95 (s, 3H, NCOCH₃), 2.48-2.66 (m, 2H, CH₂ cys), 2.88-3.02 (m, 2H, H5, H5' Thz), 3.24-3.34, 3.64-3.75, 3.77-3.86 (3m, 2H, H4, H4' Thz), 3.96, 4.41 and 4.45, 4.54 (2 x 2d, J = 2 x 8.8 and 2 x 10.3 Hz, 2H, H2, H2' Thz), 4.60-4.69 (m, 1H, α H cys), 6.05-6.15 (m, 1H, NH cys), 7.18-7.34, 7.36-7.44 (2m, 15H, aromatic H).

MS: (FAB⁺/G-T) m/z 953 (2M+H)⁺, 477 (M+H)⁺.

Analysis: C₂₇H₂₈N₂O₂S₂ (476)

Calc. %:	C	68.07	H	5.88	N	5.88
Found %:		67.97		5.84		5.89

2.46. N-(N-ACETYL-L-CYSTEINYL)THIAZOLIDINE (I-212)

This compound is obtained by the S-detritylation of **18** (0.77 mmol). The protocol used is the same as that described in example 1 for the synthesis of **I-152**. After stirring overnight at ambient temperature, a solution is obtained. This solution is evaporated to dryness under vacuum and the pasty residue obtained is coevaporated with toluene (3 x 5 ml) and then washed with 4 x 15 ml of ether to provide the corresponding silver sulfide in the form of a yellow powder. This sulfide is subsequently treated in the same way as that described in example 1. After the various treatments, a

translucent gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: AcOEt). **I-212** is isolated in the form of a colorless gum with a yield of 64%. R_f (AcOEt/MeOH, 9.7/0.3): 0.40. Crystallizes from an AcOEt/hexane mixture in the form of colorless needles. M.p. = 90-91°C. $[\alpha]_D^{20} = -31^\circ$ (c 1, CHCl₃).

¹H NMR (CDCl₃) δ ppm (isomeric mixture, 5.8/4.2): 1.55 (app. t, J = 8.9 Hz, 1H, SH), 2.02 (s, 3H, NCOCH₃), 2.75-2.84, 2.85-2.95 (2m, 2H, CH₂ cys), 2.99-3.18 (m, 2H, H5, H5' Thz), 3.79-4.03 (m, 2H, H4, H4' Thz), 4.57, 4.63 and 4.71 (2d, J = 2 \times 10.4 and 1 app. s, 2H, H2, H2' Thz), 4.94-5.04 (m, 1H, α H cys), 6.41-6.52 (m, 1H, NH cys).

MS: (FAB⁺/G-T) m/z 235 (M+H)⁺.

Analysis: C₈H₁₄N₂O₂S₂ (234)

Calc. %: C 41.03 H 5.98 N 11.97

Found %: 41.12 6.01 11.96

2.47. *N*-(*N,S*-BISACETYL-*L*-CYSTEINYL)THIAZOLIDINE (**I-213**)

The S-acylation of **I-212** (0.26 mmol) with acetic anhydride is carried out according to the general method described in example 2. The reaction mixture is subsequently treated according to the protocol described for the synthesis of **1-177**. After the various treatments, a gum is collected, which gum is purified by flash chromatography on a silica gel column (eluent: AcOEt/petroleum ether 10%). **I-213** is isolated in the form of a gum (Yd = 80%) which crystallizes from an AcOEt/petroleum ether mixture in colorless needles. R_f (AcOEt): 0.3, M.p. 107-108°C. $[\alpha]_D^{20} = +6.6^\circ$ (c 1.36, CHCl₃).

¹H NMR (CDCl₃) δ ppm (isomeric mixture, 5.9/4.1): 2.01 (s, 3H, NCOCH₃), 2.36 (s, 3H, SCOCH₃), 2.97-3.20, 3.26-3.29, 3.30-3.33 (3m, 4H, CH₂ cys, H5, H5' Thz), 3.73-3.81, 3.82-3.89, 3.96-4.06 (3m, 2H, H4, H4' Thz), 4.49, 4.61, 4.71, 4.81 (2 \times 2d, J = 2 \times 10.3 and 2 \times 8.9 Hz, 2H, H2, H2', Thz), 4.93-5.04 (m, 1H, α H cys), 6.39-

6.50 (m, 1H, NH cys).

MS: (FAB⁺/G-T) *m/z* 553 (2M+H)⁺, 277 (M+H)⁺.

Analysis: C₁₀H₁₆N₂O₃S₂ (276)

Calc. %: C 43.48 H 5.80 N 10.14

5

EXAMPLE 3: DEMONSTRATION OF ANTIVIRAL ACTIVITY OF COMPOUNDS OBTAINED IN EXAMPLES 1 AND 2

10 3.1. PREAMBLE

The manipulations of infectious material have been performed in a L3 type high security laboratory.

15 In order to approximate as closely as possible to physiopathological conditions, all the studies were carried out using MDM, PBMC or PBL primary cultures obtained from healthy blood donors.

20 In all the experiments, the effects of the novel molecules were compared with those of the reference molecules: NAC or MEA.

25 3.2. Isolation, culturing and activation of the cells

3.2.1. Culture media

30 The medium A is composed of RPMI 1640 cell culture medium (Life Technologies) supplemented with 10% of fetal calf serum (FCS, Boehringer Mannheim) heat decomplexed at 56°C for 30 min, of 2 mM of L-glutamine (Boehringer Mannheim) and of a 100 µg/ml solution of 3 antibiotics (penicillin, streptomycin and
35 neomycin; PSN, Life Technologies). The medium B is composed of medium A supplemented with 20 IU/ml of recombinant human IL-2 (Boehringer Mannheim).

3.2.2 Isolation of the peripheral blood mononuclear

0980294 430
T022T 16208650

cells

The PBMCs are separated from the other components which appear in the blood by centrifugation on a Ficoll gradient (MSL 2000, Eurobio): 30 ml of blood from a healthy donor, diluted to a third, are deposited on a 20 ml cushion of Ficoll. After centrifuging for 20 min at 850 g, the band of PBMC is removed and then washed twice in RPMI 1640, after centrifuging for 10 min at 750 g and 5 min at 400 g.

3.2.3. Isolation of the monocytes and lymphocytes

The monocytes and the lymphocytes are isolated from the PBMCs by countercurrent elutriation according to the protocol described by C. Figdor et al. (*Cell. Biophys.*, 1983, 5, 105-118). The two cell populations thus separated are immunophenotyped and then analyzed using a flow cytometer (FACScan, Becton Dickinson). The purity of the monocytes and PLBs thus obtained is greater than or equal to 95%.

3.2.4. Culturing and activation of the cells

A million monocytes in 1 ml of culture medium A are distributed in each well of a 48 well plate (Becton-Dickinson). The monocytes are left to differentiate into macrophages for 7 days. The macrophages thus differentiated are maintained in culture in medium A.

For some experiments, the PBMCs and the PBLs are activated for 48 h with 1 µg/ml of a mitogen, PHA-P (Difco Laboratories). The PBMCs and the PBLs are cultured in medium A (quiescent) or B (activated). The cells are cultured at 37°C in an atmosphere saturated with moisture under 5% of CO₂. The culture supernatants are removed and the culture media are replaced every three or four days. At each renewal of the culture media, the cell viability is evaluated by coloring with

trypan blue or by microscopic observation.

3.3. Evaluation of the antiviral activity of I-152 and of its derivatives

5

3.3.1. Preparation of the compounds

During the first series for evaluation of the antiviral activity and during the study of the mechanism of action of I-152, I-152 and the reference products were dissolved in medium A. The molecules were resuspended at stock concentrations (NAC: 20 mM, MEA and I-152: 10 mM) and were stored at -80°C. The dilutions were subsequently prepared extemporaneously in medium A.

15

During the second series for evaluation of the antiviral activity, I-152 and its derivatives (insoluble in medium A) were dissolved in DMSO and then diluted in medium A. The concentration of DMSO during this study is 1.5%. The solutions and the dilutions were prepared extemporaneously in order to avoid or reduce oxidation of I-152 by DMSO to its disulfide.

20

3.3.2. Virus and infection of the cells

25

The MDMs were infected with the reference isolate with macrophage tropism, HIV-1/Ba-L. The PBMCs and the PBLs were infected with the reference isolate with lymphocyte tropism HIV-1 LAI. The viral stock were formed by amplifying these strains *in vitro* using umbilical blood mononucleated cells (UBM(s)) preactivated with 1 µg/ml of PHA-P and cultured in medium A supplemented by 20 IU/ml of IL-2. In order to remove the soluble factors, such as cytokines, the culture supernatants were ultracentrifuged at 360 000 g for 5 min, and the pellets were resuspended in RPMI 1640. The viral stocks thus formed were subsequently titred using PBMCs activated with PHA-P. The TCID₅₀s (50% Tissue Culture Infectious Dose) were calculated

30

35

using the Kärber formula.

A million MDMs were infected with 10 000 TCID₅₀s of the HIV-1/Ba-L strain. This amount of virus corresponds to a multiplicity of infection (m.o.i.) equal to 0.01. The excess of virus is removed 24 h after by washing with cells using RPMI 1640. The PBLs and the PBMCs were infected with 10 000 TCID₅₀s of the HIV-1 LAI strain (moi = 0.01). The cells were washed at the end of the second day of infection.

3.3.3. Assaying the viral replication in the culture supernatants

3.3.3.1 Assaying the reverse transcriptase (RT) activity

The viral replication is measured by assaying the RT activity in the culture supernatants according to the technique described by F. Rey et al. (*Biochem. Biophys. Res. Comm.*, 1984, 121, 126-133). The radioactivity incorporated during the extension of the complementary strand of a poly-rA synthetic matrix in the presence of an oligo-dT₁₂₋₁₈ primer and of a radiolabeled substrate, [³H-methyl]thymidine-5'-triphosphate ([³H]TTP), makes it possible to assay the enzymatic activity of RT. 400 µl of supernatant are ultracentrifuged at 360 000 g for 5 min. The RT is released by lysis of the viral pellet in 20 µl of NTE-Triton (100 mM NaCl, 10 mM Tris, 1 mM EDTA, 0.1% Triton X-100). These 20 µl are subsequently incubated with 40 µl of the following reaction mixture: 62.5 mM Tris, pH 7.8; 25 mM KCl; 6.25 mM MgCl₂; 1.25 mM dithiothreitol (DTT); 2.5×10^{-3} ODU oligo-dT₁₂₋₁₈ and poly-rA, 5.55×10^{-3} TBq [³H]TTP. After one hour at 37°C, the enzymatic reaction is halted and the newly synthesized strands are precipitated for 20 min at 4°C by the addition of 1 ml of sodium pyrophosphate (NaPP), of 50 µl of yeast DNA (0.1 mg/ml in 5% trichloroacetic acid (TCA)), and of 4 ml of 20% TCA. The mixture is filtered using a cellulose acetate membrane (Millipore)

which retains the radiolabeled poly-dT chains. The filter is washed using 20 ml of 5% TCA and the residual water is removed by addition of 25 μ l of 70% ethanol. The filter is dried in an oven for 10 minutes at 80°C and is then introduced into vials containing 8 ml of liquid scintillant. The β radioactivity is quantified by means of a scintillation counter (Packard Bell). The results are expressed in pM of [3 H]-TMP incorporated/h/ml of supernatant or, more simply, in cpm/h/ml.

3.3.3.2 Assaying the P25 protein

The assaying of the p25 protein is carried out using the ELISA kit from DuPont de Nemours. 200 μ l of the culture supernatant to be tested are placed in a well of a microtitration plate. The addition of 20 μ l of lysis buffer releases the viral proteins in the medium. The released antigen attaches to a mouse anti-p25 monoclonal antibody immobilized at the bottom of the wells. After incubating for 2 h at 37°C, 3 washing operations using 5 ml of washing buffer are carried out and then 100 μ l of a biotinylated polyclonal antibody which reacts with the immobilized antigen are incubated for 1 h at 37°C. The series of 3 washing operations in the same buffer and with the same volume is again carried out before the addition over 15 min at 37°C of 100 μ l of Raifort-streptavidin peroxidase conjugate which will make it possible to amplify the colorimetric reaction. The complex formed is revealed, after 3 washing operations using 5 ml of the washing buffer of the kit, with 100 μ l of o-phenylenediamine (OPD) dihydrochloride. After incubating for 30 min at ambient temperature, the reaction is halted by the addition of 100 μ l of 4N sulfuric acid. The OD of the coloring thus obtained is read at 490 nm. This absorbence is directly proportional to the amount of attached antigen. The linear relationship relating the O.D. to the p25 concentration is established by virtue of a standard

range produced from a recombinant p25 solution.

3.3.4. Analysis of the results and determination of the 50% effective doses

5

The 50% effective doses (ED50) are calculated from the cumulative RT activities using the software "Dose-effects analysis with microcomputers" developed by J. Chou & T.C. Chou.

10

3.3.5. Measurement of the cell viability

These tests are carried out systematically in parallel with the evaluation of the antiviral activity. In view of the oxidation/reduction capacity of the molecules tested, the test with the tetrazolium salt, which measures the activity of mitochondrial dehydrogenases, cannot be used.

20 *3.3.5.1. Measurement using an exclusion dye, trypan blue*

The nonadherent cells, such as the PBMCs and the PBLs, are counted using a Malassez cell and an exclusion dye, trypan blue (TB). 25 µl of the cell suspension are added to 475 µl of TB. This count is carried out after the isolation of the PBMCs and the PBLs, before the plating, and at each replacement of the culture medium.

30 *3.3.5.2. Measurement using a vital dye, neutral red*

Neutral red (NR) is a vital dye which makes it possible to measure the viability of adherent cells, such as MDMs. 600 µl of culture supernatant are removed and replaced with 400 µl of an NR solution (0.001% m/v in phosphate buffer, PBS, Boehringer Mannheim), filtered at 0.45 µm. The cells were incubated for 1 h at 37°C and are subsequently washed (2 × 1 ml of PBS). The cells are then lysed at -20°C with 200 µl of a 50%

ethanol mixture comprising 1% of glacial acetic acid. The OD is measured twice with 100 µl of solution using a spectrophotometer.

5 **3.4. Study of the mechanism of action of I-152**

3.4.1. Quantification of the proviral DNAs by PCR

I-152 is composed of MEA and NAC, which are capable of
10 interacting with the early phases of the biological
cycle of HIV. It is therefore capable of decreasing the
integration of the provirus into the cell genome. In
order to measure these effects, the proviral DNAs were
quantified by PCR. The cells were lysed using 1 ml of
15 the following lysis solution: 10 mM Tris HCl pH 8;
100 mM of EDTA pH 8; 0.5% of sodium dodecyl sulfate
(SDS); 20 µg/ml of DNase-free bovine pancreatic RNase.
200 µg/ml of proteinase K are subsequently added to
this suspension. The DNAs were subsequently extracted
20 using 1 ml of an ice-cold saturated phenol solution and
1 ml of a phenol/Chisam solution.

The viral DNAs were then amplified by means of specific
primers of the *gag* gene (SK01/SK39) and of a standard
25 range of the 8E5 line, a chronically infected line, the
cells of which carry a proviral copy. The β-globin gene
was used as reporter gene in order to make sure of the
quality of the DNA extraction.

30 3.4.2. Acellular test of the enzymatic activity of RT

The I-152 molecule is composed of NAC and MEA, which
are capable of inhibiting the activity of RT
(A. Bergamini et al., *J. Clin. Invest.*, 1994, 93,
35 2251-2257). For this reason, the inhibiting capacity of
I-152 with respect to the RT activity was measured
using an acellular test. This test was carried out
according to the protocol described above (§ 3.3.3.1.).
In the reaction mixture, only the 20 µl of water are

09980291.112701

replaced by 20 µl of a concentration of I-152 or of the reference compounds. Heparin, known for inhibiting the activity of RT and of the other DNA polymerases, is used as positive control for inhibition.

5

3.4.3. Assaying the total glutathione

The method for assaying the total glutathione (GSH + GSSG) which we used is an adaptation, to the MDM culture system, of that described by O.W. Griffith et al. (*Anal Biochem.*, 1980, 106, 207-212). The assayings were carried out 24 h after the beginning of the treatment by the various compounds. A million cells are washed three times in PBS and then lysed with 150 µl of a lysis buffer (0.1M phosphate pH = 7.4; 0.15M NaCl; 0.1% BSA, 0.01% Azide, 0.1% Triton X-100; 0.05% 5'-sulfosalicylic acid). The standard range in doubling dilutions ranges from 50 µM to 1.5 nM of GSSG or of GSH. The test is carried out in triplicate. 85 µl of 0.6 mM NADPH, 25 µl of 6 mM DTNB and 130 µl of pure water are added to the samples. The latter are incubated at 30°C for 10 min. At the time of reading, 20 µl of 1 U/ml GSSG reductase are added to all the wells. The absorbence is measured with the long pathway at 412 nm. The concentration of total glutathione is subsequently determined with respect to the values of the calibration curve, produced in parallel with the assaying, and by extrapolation in the region of the linear part of the curve.

30

EXAMPLE 4: ANTI-HIV ACTIVITY OF I-152 WITH RESPECT TO MACROPHAGES

4.1 Antiviral activity of I-152 with respect to MDMs infected extemporaneously

35

4.1.1. 50, 70 and 90% Effective doses and cytotoxicity of I-152

The cells of the macrophage line play a major role in oxidative "processes". The pro-GSH molecule, I-152, was therefore tested with respect to MDMs infected with the VIH-1/Ba-L strain. I-152, after intracellular
5 metabolization, is capable of releasing NAC, MEA and cysteine (figure 1).

We compared the activities of I-152 with those of its two components, NAC and MEA, in our experimental
10 system. I-152 has a strong antiviral activity superior to that of NAC or of MEA (figure 2, table 1). The inhibiting concentrations of NAC, of MEA and of I-152 are respectively equal to 9.4 mM, 300 μ M and 50 μ M. In the light of these figures, I-152 therefore appears to
15 be 6 and 188 times more effective than MEA and NAC. However, these values do not reflect the difference between these three products. This is because, at antiviral doses, NAC and MEA are cytotoxic whereas I-152 is not cytotoxic. Thus, NAC is cytotoxic from 10
20 or 15 mM (figure 3: NAC 15mM: 70% cytotoxicity; NAC 40 mM: 91%), and MEA decreases the viability of MDMs by 65% at the concentration of 500 μ M (figure 3). On the other hand, I-152, even at doses 10 times greater than its 50% effective dose (ED), is not cytotoxic (figure
25 3: 500 μ M).

4.1.1.2. Effect of I-152 on the production of the major protein of the viral nucleocapsid

30 The viral replication can be measured in the culture supernatants by assaying either the enzymatic activity of RT or the major protein of the viral nucleocapsid, p25. In infected MDM cultures, the inhibition of the production of the p25 protein is concomitant with that
35 of the RT activity (figure 4). These results therefore confirm the antiviral effectiveness of I-152.

4.1.1.3. Effect of the multiplicity of infection on the antiviral activity of I-152

During our first experiments, the cells were infected using 10 000 TCID₅₀ (m.o.i.: 0.01). In order to measure the effects of the viral load on the anti-HIV activity of I-152, the cells are infected, in a second step, using 1 000 TCID₅₀ (m.o.i.: 0.001).

The antiviral activity of I-152 increases when the m.o.i. is decreased (figure 5) and the ED turns out to be decreased thereby (table II, 3 μ M vs. 50 μ M).

4.1.2. Antiviral activity of I-152 with respect to preinfected MDMS

The treatment of the cells 7 days after infection confirms the antiviral activity of I-152 (figure 6). This is because, at a dose of 500 μ M, viral replication is extinguished. However, under these experimental conditions, the dose of 250 μ M is ineffective. This shift in the inhibiting potential, observed between the various methods of treatment, suggests 1) that I-152 inhibits viral replication by probably combining two mechanisms: an early and a late mechanism, and 2) that, at high dose (\geq 500 μ M), inhibition of the late phase of the biological cycle is sufficient.

4.2. Antiviral activity of I-152 in primary cultures of lymphocytes and of peripheral blood mononuclear cells

After having shown the antiviral activity of I-152 with respect to cells of the macrophage line, its effects were measured with respect to peripheral blood lymphocytes (PBLs) and mixed population comprising monocytes/macrophages and lymphocytes, PBMCs. Furthermore, in order to measure the effects of cell activation on the antiviral activity of I-152, the cells were or were not activated by a mitogen, phytohemagglutinin-P (PHA-P).

4.2.1. Viability of the PBMCs and PBLs treated with I-152

5 The cell viability was measured in parallel with the
assessment of the antiviral activity. At each
replacement of the culture medium, the viable cells
were counted by means of an exclusion dye, trypan blue.
In the PBMC and PBL cultures, I-152 is not cytotoxic.
10 This is because the viability of the lymphocytes is not
decreased in the PBL and PBMC cultures and,
furthermore, in the latter, when the cells are not
exposed to PHA-P, the monocytes differentiate into
macrophages with a pseudofibroblastic appearance. On
15 the other hand, NAC and MEA are cytotoxic for both cell
types from doses of 10 or 15 mM and 500 μ M
respectively.

4.2.2. Antiviral activity of I-152 with respect to
20 quiescent PBMCs or PBMCs activated by PHA-P, and
infected

The PBMCs, quiescent or activated by PHA-P, were
infected by the reference strain with lymphocyte
25 tropism HIV-1 LAI. All the culturings were carried out
in parallel and the drugs were maintained throughout
the culturing.

In both cell populations, MEA and NAC do not inhibit
30 viral replication at known cytotoxic doses (results not
presented). In the quiescent PBMCs, I-152 inhibits
viral replication by 97 and 88% at doses of 250 and
125 μ M respectively and, in the activated PBMCs viral
replication is decreased by 42 and 25% at the same
35 doses (figure 7).

4.2.3. Antiviral activity of I-152 with respect to
quiescent PBLs or PBLs activated by PHA-P, and infected
with the HIV-1 LAI strain

0980291 470
T022T 16208550

As in the PBMCs cultures, MEA and NAC do not have or have a very slight antiviral activity in PBLs (results not presented). On the other hand, I-152 inhibits viral replication in quiescent PBLs or PBLs activated by PHA-P (figure 8).

4.3. Anti-HIV activity of I-152 with respect to tissue macrophages

4.3.1. Isolation of spleen monocytes/macrophages

The spleen is dissected and sieved and then the mononuclear cells are isolated using a density gradient, on a Ficoll cushion. The monocytes/macrophages are obtained by adherence to the plastic. The monocytes were allowed to differentiate into macrophages for 7 days, at which time they were infected.

4.3.2. Results

The monocyte/macrophage plays a deleterious role in the physiopathology of infections by the HIV as it constitutes an important site for retroviral replication within tissues. As these tissues are not very accessible to current anti-HIV therapy, this cell population is regarded as a "reservoir".

Retroviral replication within this cell population, and thus the effectiveness of a molecule such as I-152, is conditioned partly by the level of cell differentiation. It was therefore important to make sure of the antiviral effectiveness of I-152 in monocytes/macrophages with a degree of maturation which can be different from that of MDMs. We have thus evaluated the antiviral activity of I-152 and its ability to regenerate the intracellular level of GSH in spleen macrophages. In this cell populations, the

HIV-1/Ba-L strain also replicates at high noise. The I-152 molecule has proved to be as effective in human spleen macrophages as in macrophages derived from blood monocytes. This is because the concentration of 38 μ M decreases HIV replication by 50% in this spleen cell population (table III). Likewise, as in the macrophages derived from blood monocytes, I-152 increases the intracellular level of GSH in a dose-dependent way which can be saturated from 250 μ M (figure 15). It should be noted that, in the spleen macrophages, as in the macrophages derived from blood monocytes, infection by HIV leads to a deficiency of GSH (MDM; figure 16).

4.4. Mechanism of action of I-152

4.4.1. Effect of I-152 on the integration of the proviral genome within the cell genome

Cell culture experiments would suggest that I-152 inhibits HIV replication by probably combining two mechanisms, the one early and the other late. In order to measure the effects of this molecule on the early phases of the biological cycle of the HIV, the integration of the provirus within the cell genome was quantified by PCR. I-152 inhibits the integration of the provirus. This inhibition is much greater than that induced by NAC or MEA. On the other hand, it is not perfect, unlike that induced by 10 μ M AZT (figure 9).

4.4.2. Effect of I-152 on the enzymatic activity of RT in an acellular system

In view of the preceding results and because MEA is capable of inhibiting the activity of RT, the effects of I-152 on the activity of this enzyme were measured in an acellular system. The experiment was carried out in duplicate and heparin was used as control of the inhibition of the activity RT. In both cases, heparin at the concentration of 1 mg/ml completely inhibits the

RT activity of the HIV-1 LAI isolate. This inhibition is dose-dependent. Likewise, MEA decreases by $29 \pm 1\%$ (exp. 1, figure 10) and $48 \pm 4\%$ (exp. 2 not presented) at a dose of $500 \mu\text{M}$. On the other hand, NAC and I-152 do not exhibit an inhibiting activity with respect to the RT of the HIV in our experimental system (figure 10). These results confirm that I-152, by releasing MEA, can interact with an early stage of the biological cycle of the HIV.

4.4.3. Effect of I-152 on the intracellular concentration of glutathione

The late effects of I-152 are probably the more direct consequence of its proglutathione activity. In order to make sure of this activity in lymphocytes and macrophages, the intracellular concentrations of total glutathione (GSH + GSSG) were determined in PBMC cultures (figure 11). Of the two reference molecules, NAC is better at increasing the intracellular level of glutathione in quiescent PBMCs. This is because MEA does not significantly alter the intracellular level of glutathione, at the very least at the doses tested. In our experiments, the doses of NAC used are higher than those of MEA, which may explain the difference observed in the intracellular level of glutathione.

I-152 increases the intracellular level of glutathione. This increase follows a bell-shaped curve with an optimum at 25 and $125 \mu\text{M}$. The dose of I-152 of $125 \mu\text{M}$ increases the cellular concentration up to $2.64 \pm 0.13 \mu\text{M}$. This intracellular concentration is equivalent to that obtained with the dose of NAC of 15 mM . On considering the concentrations of molecules supplementing the culture medium, I-152 is 120 times more active than NAC, It should be noted that the intracellular concentrations of glutathione decrease at high concentrations, at the very least for MEA ($500 \mu\text{M}$) and I-152 ($250 \mu\text{M}$). This phenomenon is probably the

consequence of the processes for the regulation of glutathione.

5 **4.5 Antiviral activity of the S-acylated
derivatives of I-152: I-176, I-177 and I-178, with
respect to MDMs infected extemporaneously**

During a second series of experiments, the antiretroviral activities of the I-152 derivatives were
10 tested with respect to MDMs infected by the HIV-1/Ba-L strain (figure 12). These molecules are lipophilic and were thus dissolved in dimethyl sulfoxide (DMSO) and then diluted. I-152, which acts as reference, was treated in the same way. Under these experimental
15 conditions, I-152 proved to be the most effective in inhibiting viral replication. However, it should be noted that DMSO decreases its antiviral effectiveness and that the standard deviation is high as the antiviral activity was decreased with respect to two of
20 the three wells of the culture triplicate. The compound I-176 is slightly toxic at 150 μ M, which may also explain the variability within the culture triplicate and the size of the standard deviation observed. To date, none of the S-acylated derivatives has shown, in
25 vitro, an activity superior to that of the mother molecule. Nevertheless, I-177 and I-178 have activities similar to that of I-152, and, in view of the importance of the latter, these two molecules, which are more lipophilic, are to be retained. It may have
30 advantages in the case of clinical experimentations. This is because they can have pharmaceutical dosage forms and methods of administration different from those of I-152.

35 **EXAMPLE 5: EFFECT OF I-152 ON THE INTRACELLULAR
CONCENTRATION OF GSH**

5.1. Materials and methods

With the exception of materials and methods presented below, the procedures are similar to those described in the preceding examples.

- 5 The intracellular GSH was assayed by means of the assay kit sold by Cayman. This method for assaying glutathione is an adaptation of that described by O.W. Griffith *et al.* (1980).
- 10 The compound I-152 and its derivatives are prepared extemporaneously by being dissolved in dimethyl sulfoxide (DMSO) at the concentration of 100 mM. They are subsequently stored at -20°C after having been diluted 10 fold in phosphate buffer (PBS).

15

5.2. Results

- The effects of the compound I-152 in increasing the intracellular concentration of GSH were demonstrated in
- 20 cells not exposed to an oxidative stress. The present results show that this molecule is also capable of regenerating an abnormally low intracellular level. This is because the infection of macrophages derived from human blood monocytes (MDMs) leads to an
- 25 intracellular deficiency of GSH (figure 13); this deficiency is accompanied by an increase in the expression of the enzymes involved in maintaining this level and by an increase in 8-isoprostane, evidence of an oxidative stress (results not presented).

30

EXAMPLE 6: EFFECT OF I-152 ON THE MACROPHAGE SYNTHESIS OF TNF- α

6.1. Materials and methods

35

With the exception of materials and methods presented below, the procedures are similar to those described in the preceding examples.

The synthesis of tumor necrosis factor (TNF- α) was modified in the MDM culture supernatants using the colorimetric kit sold by Cayman.

5 The compound I-152 and its derivatives are prepared extemporaneously by being dissolved in dimethyl sulfoxide (DMSO) at the concentration of 100 mM. They are subsequently stored at -20°C after having been diluted 10 fold in phosphate buffer (PBS).

10

6.2. Results

15 Tumor necrosis factor (TNF- α), like the oxygen-comprising or nitrogen-comprising radical components, plays a major role in the apoptotic processes associated with infection the HIV. Furthermore, the radical components can promote the synthesis of this proinflammatory cytokine. For this reason, the effects of I-152 in decreasing the synthesis of TNF- α were thus
20 looked for in MDMs stimulated by a bacterial lipopolysaccharide and interferon (IFN- γ). The compound I-152 inhibits the synthesis of TNF- α and increases the concentration of GSH under these experimental conditions (figure 14).

25

EXAMPLE 7: POTENTIATION OF THE ANTIRETROVIRAL ACTIVITY OF AZT BY THE COMPOUND I-152

7.1. Materials and methods

30

With the exception of materials and methods presented below, the procedures are similar to those described in the preceding examples.

35 Viral replication was measured by assaying the reverse transcriptase activity in culture supernatants using the RetroSys kit from Innovagen, following the recommendations of the company.

0980291 11201

The compound I-152 and its derivatives are prepared extemporaneously by being dissolved in dimethyl sulfoxide (DMSO) at the concentration of 100 mM. They are subsequently stored at -20°C after having been
5 diluted 10 fold in phosphate buffer (PBS).

7.2. Results

The pro-GSH compounds of the "I-152 family" are
10 preferably administered as adjuvants therapeutic for current antiretrovirals. The inventors have thus attempted to measure *in vitro* the effects of I-152 with respect to the anti-HIV effectiveness of these molecules. This study was carried out using macrophages
15 derived from human blood monocytes infected by the HIV-1/Ba-L strain and according to the methodology described by J. and T.C. Chou for quantifying the synergistic effects, additive or antagonistic, between two molecules.

20 In our experimental model, the compound I-152 potentiates the anti-HIV activity of AZT. This is because the combination index (CI) is less than 1, which testifies to a synergy between the two compounds
25 tested (figure 17).

EXAMPLE 8: ANTIRETROVIRAL ACTIVITY OF THE ACYLATED ANALOGUES OF I-152 OR OF ITS DERIVATIVES

30 8.1. Materials and methods

With the exception of materials and methods presented below, the procedures are similar to those described in the preceding examples.

35 The 50% effective doses (ED50) are calculated from the cumulative RT activities using the software "Dose-effects analysis with microcomputers" developed by J. Chou and T.C. Chou.

The compound I-152 and its derivatives are prepared extemporaneously by being dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mM. They are subsequently stored at -20°C after having been diluted 10 fold in phosphate buffer (PBS).

8.2. Results

The anti-HIV activity of about twenty I-152 derivatives, in addition to that of the S-acylated compounds I-176, I-177 and I-178, was evaluated in the system of MDMS infected *in vitro* by the HIV-1/Ba-L strain. These compounds attempted, to some extent, to be more lipophilic; they are thus capable of making possible pharmaceutical dosage forms and methods of administration different from those of I-152. Furthermore, these derivatives constitute the first link in the structure-activity study which should make it possible to identify important residues in the activity of this family of compounds. The "stock" solutions of these compounds were treated with ultrasound in order to improve the solubility of the products.

Nine compounds demonstrated a significant antiviral activity of the same order as that of I-152 (tables IV and V). The values obtained with the compound I-152 which are presented in these two tables perfectly illustrate the reproducibility of the anti-HIV effects of I-152 from one experiment to another and/or from one cell donor to another. This is because the values presented in table III result from a first experiment carried out using cells from one donor and those presented in table IV from a second experiment carried out using cells from another donor.

In conclusion, the compound I-152 or one of its analogues or of its derivatives constitutes an

excellent adjuvant therapeutic for current antiretrovirals, such as AZT, and optionally for other classes of antiretroviral molecules currently used in human clinical treatment (i.e. nonnucleoside reverse transcriptase inhibitors and viral protease inhibitors) while being capable of reorganizing both damage to the immune system and that to the oxidative metabolism. Furthermore, these results have demonstrated the biological activities of other molecules which are derivatives and/or analogues of I-152, the subject matter of the present invention; which henceforth constitutes a family of molecules which are biologically active and which can potentially be used as therapy.

The ability to increase the intracellular level of GSH and also to regenerate this tripeptide under conditions of stress where reference molecules, such as NAC and MEA, are ineffective is also highly advantageous. These powerful antioxidant and probably antiapoptotic (if it is considered that the radical components and TNF- α play a major role in these deleterious processes) activities are in favor of a promotion of the compound I-152 in other noninfectious situations.

25

05990291 112701


REFERENCES

- Abrams, 1991, Am. J. Med., 91, 106-112.
- 5 Barnett et al., 1969, J. Amer. Chem. Soc., 91,
2358-2369.
- Bergamini et al., 1994, J. Clin. Invest., 93,
2251-2257.
- 10 Bosegaard et al., 1993, J. Pharmacol. Exp. Ther., 265,
1239-1244.
- Brückner et al., 1989, J. Chromatogr., 476, 73-82.
- 15 Figdor et al., 1983, Cell, Biophys., 5, 105-118.
- Griffith et al., 1980, Anal. Biochem., 106, 207-212.
- 20 Heller et al., 1997, Advances in Pharmacology, 38,
629-638.
- Herzenberg et al., 1997, Proc. Natl. Acad. Sci., 94,
1967-1972.
- 25 Horowitz, 1991, Am. J. Med., 91, 113-117.
- Rabinovitch et al., 1992, Diabetologie, 35, 409-413.
- 30 Rey et al., 1984, Biochem. Biophys. Res. Comm., 121,
126-133.
- Volante, 1981, Tetrahedron Lett., 22, 3119-3122.
- 35 Wieland and Bokelman, 1952, Ann. Chem., 576, 20-34.
- Zee-cheng et al., 1970, J. Med. Chem., 13, 414-418.

09980291 142701

CLAIMS

1. A compound of general formula:



in which:

- R and R' independently represent a linear or branched C₁-C₇ alkyl radical or an aryl group which is unsubstituted or substituted by one or more radicals chosen from halogens, linear or branched C₁-C₃ alkyl radicals and -OH radicals;
- R'' is hydrogen or a CO-R¹ group in which R¹ is a linear or branched C₁-C₇ alkyl radical or an aryl group which is unsubstituted or substituted by one or more radicals chosen from halogens, linear or branched C₁-C₃ alkyl radicals and -OH radicals;

and the dimers formed by a disulfide bridge from one and/or other of the two sulfur atoms of the compounds of general formula I composed of the R'' radicals or of the R'CO- radicals of the two molecules, and the corresponding thiazolidine forms.

2. The compound as claimed in claim 1, characterized in that R is a methyl group (-CH₃).
3. The compound as claimed in claim 2, characterized in that R' is a methyl group (-CH₃).
4. The compound as claimed in claim 3, characterized in that R'' is hydrogen (Compound N-(N-acetyl-L-cysteinyl)-S-acetylcysteamine).

5. The compound as claimed in claim 3, characterized in that R'' is an acetyl group ($-\text{COCH}_3$) (Compound N-(N,S-bisacetyl-L-cysteinyl)-S-acetylcysteamine).
6. The compound as claimed in claim 3, characterized in that R'' is an isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$) (Compound N-(N-acetyl-S-isobutyryl-L-cysteinyl)-S-acetylcysteamine).
7. The compound as claimed in claim 3, characterized in that R'' is a pivaloyl group ($-\text{COC}(\text{CH}_3)_3$) (Compound N-(N-acetyl-S-pivaloyl-L-cysteinyl)-S-acetylcysteamine).
8. The compound as claimed in claim 2, characterized in that R' is selected from the isopropyl group ($-\text{CH}(\text{CH}_3)_2$), the tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and the phenyl group ($-\text{C}_6\text{H}_5$).
9. The compound as claimed in claim 8, characterized in that R'' is selected from hydrogen ($-\text{H}$), the acetyl group ($-\text{COCH}_3$), the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$), the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$) or the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).
10. The compound as claimed in claim 1, characterized in that R is an isopropyl group ($-\text{CH}(\text{CH}_3)_2$).
11. The compound as claimed in claim 10, characterized in that R' is selected from the methyl group ($-\text{CH}_3$), the isopropyl group ($-\text{CH}(\text{CH}_3)_2$), the tert-butyl group ($-\text{C}(\text{CH}_3)_3$) and the phenyl group ($-\text{C}_6\text{H}_5$).
12. The compound as claimed as claim 11, characterized in that R'' is selected from hydrogen ($-\text{H}$), the acetyl group ($-\text{COCH}_3$), the isobutyryl group ($-\text{COCH}(\text{CH}_3)_2$), the pivaloyl group ($-\text{COC}(\text{CH}_3)_3$) or

the benzoyl group ($-\text{CO}-\text{C}_6\text{H}_5$).

13. The compound as claimed in claim 8, characterized in that R'' is the trityl group.
14. The compound as claimed in claim 11, characterized in that R'' is the trityl group.
15. The compound as claimed in claim 1 to 14, characterized in that it is in the thiazolidine form.
16. A process for the preparation of the compound as claimed in any one of claims 1 to 14, characterized in that it comprises the following stages:
- a) protection of the N-acyl-L-cysteine to provide the N-acyl-S-trityl-L-cysteine compound; then
 - b) coupling of the protected N-acyl-S-trityl-L-cysteine with the S-acylcysteamine hydrochloride to provide the N-(N-acyl-S-trityl-L-cysteinyl)-S-acylcysteamine compound.
17. A process for the preparation of the compound as claimed in claim 15, characterized in that it comprises the following stages:
- a) protection of the N-acyl-L-cysteine to provide the N-acyl-S-trityl-L-cysteine compound; then
 - b) coupling of the protected N-acyl-S-trityl-L-cysteine with thiazolidine.
18. The process as claimed in claims 16 and 17 for the preparation of the compound as claimed in claims 1 to 12 and 15, characterized in that it additionally comprises the following stages:
- c) deprotection of said compound obtained in said stage b); then
 - d) release of the free thiol of formula I.

19. The process as claimed in claims 16 and 18 for the preparation of the compound as claimed in claim 4, characterized in that said N-acyl-S-trityl-L-cysteine compound of stage a) is the compound N-acetyl-S-trityl-L-cysteine and in that said S-acylcysteamine hydrochloride of stage b) is S-acetylcysteamine hydrochloride.
20. The process as claimed in claim 18 for the preparation of the compound as claimed in claims 1 to 3, 5 to 12 and 15, characterized in that it additionally comprises an S-acylation stage e).
21. A process for the preparation of the compound as claimed in claim 1 in which $R = R'$ and R'' is a hydrogen, characterized in that it comprises the following stages:
- a) esterification of the carboxyl functional group of N-Boc-L-serine (1) with N-hydroxysuccinimide in N,N-dimethylformamide (DMF) in the presence of 1,3-dicyclohexylcarbodiimide (DCC) to form the active ester (1'); then,
 - b) *in situ* condensation of the active ester formed (1') with ethanolamine (2) to provide the compound N-(N-Boc-L-seryl)-2-aminoethanol (3); then,
 - c) Mitsunobu reaction on the compound (3) with triphenylphosphine and diisopropyl azodicarboxylate in the presence of thiocarboxylic acid in tetrahydrofuran to provide the compound N-(N-Boc-S-acyl-L-cysteiny)-S-acylcysteamine (4); then,
 - d) deprotection of the compound (4) with trifluoroacetic acid.
22. The process as claimed in claim 21 for the preparation of the compound as claimed in claim 4, characterized in that said thiocarboxylic acid of stage c) is thioacetic acid.

23. A process for the preparation of the compound as
claimed in claims 1 to 3 and 5 to 12 by
S-acylation of the compound of claim 4 in solution
in pyridine in the presence of an anhydride R_2O or
of an acid chloride $R-Cl$, characterized in that R
is chosen from the $CO-R^1$ group in which R^1 is a
linear or branched C_1-C_7 alkyl radical or an aryl
group which is unsubstituted or substituted by one
or more halogen atoms.
24. A process for the preparation of the compound as
claimed in claim 5 by S-acylation of the compound
of claim 4 in solution in pyridine in the presence
of acetic anhydride.
25. A process for the preparation of the compound as
claimed in claim 6 by S-acylation of the compound
of claim 4 in solution in pyridine in the presence
of isobutyryl chloride.
26. A process for the preparation of the compound as
claimed in claim 7 by S-acylation of the compound
of claim 4 in solution in pyridine in the presence
of pivaloyl chloride.
27. The precursor of a compound involved in the route
for the biosynthesis of glutathione, characterized
in that it is the compound as claimed in any one
of claims 1 to 15.
28. The use of the compound as claimed in any one of
claims 1 to 15 in the preparation of a product
involved in the route for the biosynthesis of
glutathione.
29. The use as claimed in claim 28, characterized in
that said product is chosen from the group formed
by N-acetyl-L-cysteine, cysteamine and L-cysteine.

30. The use of the compound as claimed in any one of claims 1 to 15 as antioxidizing agent.
- 5 31. The compound as claimed in one of claims 1 to 15 as medicament.
32. The compound as claimed in one of claims 1 to 15 as medicament intended to increase the
10 intracellular and/or extracellular level of glutathione.
33. The use of the compound as claimed in any one of claims 1 to 15 in the preparation of medicament
15 intended to increase the intracellular and/or extracellular level of glutathione.
34. A pharmaceutical composition, in particular a dermatological composition, characterized in that
20 it comprises an effective amount of the compound as claimed in one of claims 1 to 15 and a pharmaceutically acceptable vehicle.
35. The use of the compound as claimed in one of
25 claims 1 to 15 in the preparation of a medicament or of the pharmaceutical composition as claimed in claim 34 for the treatment and/or prevention of pathologies or disorders related to an intra- and/or extracellular depletion of glutathione.
- 30 36. The use as claimed in claim 35, characterized in that said pathologies are chosen from viral infections, bacterial infections, parasitic infections, diseases of the respiratory tract,
35 neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, cancers, diseases of the immune system, diabetes and preferably type I diabetes, ophthalmic pathologies or dermatological diseases.

09580291-112701

37. The use as claimed in claim 36, characterized in that said pathologies are viral infections.
- 5 38. The use as claimed in claims 36 and 37, characterized in that said viral infections are infections caused by DNA viruses and RNA viruses, more particularly by retroid viruses, more particularly the human immunodeficiency virus (HIV) and preferably the type-1 human immunodeficiency virus (HIV-1).
- 10
39. The use as claimed in claims 36 to 38, characterized in that said compound is the compound as claimed in claim 4.
- 15
40. The use as claimed in claims 36 to 38, characterized in that said compound is the compound as claimed in one of claims 5 to 15.
- 20
41. A pharmaceutical composition for the preventive and curative treatment of AIDS and the associated affected tissues, characterized in that it comprises a therapeutically effective amount of the compound as claimed in claims 1 to 15 and a pharmaceutically acceptable vehicle.
- 25
42. A product comprising at least one compound as claimed in one of claims 1 to 15 and at least one reverse transcriptase inhibitor as combination product for a use in antiviral therapy which is simultaneous, separate or spaced out over time.
- 30
43. The product as claimed in claim 42, characterized in that said reverse transcriptase inhibitor is chosen, for example, from 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), 2',3'-dideoxycytidine (ddC), (-)-2',3'-dideoxy-3'-thiacytidine (3TC), 2',3'-didehydro-2',3'-dideoxy-
- 35

0590291.1370
FOIA b 7 - D

thymidine (d4T) and (-)-2'-deoxy-5-fluoro-3'-thiacytidine (FTC), TIBO, HEPT, TSAO, α -APA, nevirapine, BAHF or phosphonoformic acid (PFA).

- 5 44. The use as claimed in claim 35, characterized in that said pathologies are cardiovascular diseases preferably chosen from the group consisting of
10 arterial hypertension, arteriosclerosis, cerebral ischemia, cardiac ischemia, ventricular arrhythmias, ventricular fibrillation and myocardial infarction.
- 15 45. The use as claimed in claim 35, characterized in that said pathologies are ophthalmic pathologies, in particular cataracts.
- 20 46. The use as claimed in claim 35, characterized in that said pathologies are diseases of the respiratory tract, in particular pulmonary emphysema, idiopathic pulmonary fibrosis, cystic fibrosis, chronic bronchitis, acute bronchitis or adult respiratory distress syndrome.
- 25 47. The use of the compound as claimed in any one of claims 1 to 15 in the preparation of a medicament or of the pharmaceutical composition as claimed in claim 34 intended for the preventive and/or curative treatment of noise-related hearing loss.
- 30 48. The use of the compound as claimed in any one of claims 1 to 15 in the preparation of a medicament or of the pharmaceutical composition as claimed in claim 34 intended for the treatment of poisoning related to the oral or parenteral administration,
35 as or not as an overdose, of substances preferably chosen from the group consisting of acetaminophen, nitrites, ethanol, acrylonitrile and heavy metals, more particularly gold, silver and mercury.

00980294 112001

49. The use as claimed in claim 30 of the compound as claimed in one of claims 1 to 15 in the field of cosmetics.

5 50. The use as claimed in claim 49 to:

- (i) prevent, erase and treat wrinkles or fine lines of the skin; and/or
- (ii) combat cutaneous and/or subcutaneous slackening; and/or
- 10 (iii) improve the texture of the skin and rekindle the radiance of the skin; and/or
- (iv) remove undesired hairs from the skin; and/or
- (v) decrease the sizes of the pores of the
- 15 skin; and/or
- (vi) permanently deform the hair.

51. A cosmetic composition for the treatment of the skin and/or hair and/or body hair, characterized

20 in that it comprises the compound as claimed in one of claims 1 to 15 and a cosmetically acceptable excipient.

52. A process for the cosmetic treatment of the skin

25 for preventing, erasing and treating wrinkles or fine lines of the skin and/or combating cutaneous and/or subcutaneous slackening and/or improving the texture of the skin and rekindling the radiance of the skin and/or removing undesired


30 hairs from the skin and/or decreasing the sizes of the pores of the skin which comprises the application, to the skin, of the cosmetic composition as claimed in claim 51.

35 53. A process for the cosmetic treatment of the hair for the permanent deformation of the hair comprising the application, to the hair, of the cosmetic composition as claimed in claim 51.


09580291 112701
T022T 1628560

54. The use as claimed in claim 30 in the farm-produce industry and in particular for the preservation of the organoleptic and nutritional properties of drinks, in particular fruit juices, and/or food.


1/22

**FIG. 1**


2/22

**FIG. 2**


3/22

**FIG. 3**


4/22

**FIG. 4**


5/22

**FIG. 5**


6/22

**FIG. 6**


7/22

**FIG. 7**


8/22

**FIG. 8**


9/22

**FIG. 9**


10/22

**FIG. 10**


11/22

**FIG. 11**


12/22

**FIG. 12**


13/22

**FIG.13**


14/22

**FIG. 14**


15/22

**FIG. 15**

16/22

**FIG. 16**

17/22

**FIG. 17**

18/22

TABLE I

mM	NAC	MEA	I-152
	Pre-Tt	Pre-Tt	Pre-Tt
ED50	9.4 mM	300 μ M	50 μ M
ED70	11 mM	400 μ M	100 μ M
ED90	14 mM	600 μ M	250 μ M

FIG. 18

20/22

TABLE III

(μ M)	I-152
ED50	38
ED70	54
ED90	97

FIG. 20

21/22

TABLE IV

(μ M)	I-152	I-188	I-189	I-192	I-193
ED50	35	109	43	166	146
ED70	45	176	54	204	186
ED90	66	381	78	283	272

FIG. 21

22/22

TABLE V

(μ M)	I-152	I-203	I-204	I-207	I-208	I-209
ED50	43	74	74	43	36	51
ED70	68	93	91	62	50	71
ED90	141	132	127	112	88	118

FIG. 22

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL ANTIOXIDANTS, PREPARATION PROCESSES AND THEIR USES

the specification of which

XXX is attached hereto
was filed on _____ as
Application Serial No.
And was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I do not know and do not believe that the same was ever known or used in the United States of America before my invention thereof, or patented or described in any printed publication in any country before my invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, and that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 199, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
99/06708	FRANCE	27.05.1999	X	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

05580291-112701

(Application Serial No.)
PCT/FR00/01447

(Filing Date)
26.05.2000

(Status - patented, pending, abandoned)
pending

(Application Serial No.)

(Filing Date)

(Status - patented, pending, abandoned)

(Application Serial No.)

(Filing Date)


(Status - patented, pending, abandoned)

I hereby appoint BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN, a firm including :

Keith G. Askoff, Reg. No. 33,828; Aloysius T.C. AuYeung, Reg. No. 35,432; Bradley J. Bereznak, Reg. No. 33,474; Michael A. Bernadicou, Reg. No. 35,934; Roger W. Blakely, Jr.; Reg. No. 25,831; Timothy R. Croll, Reg. No. 36,771; Daniel M. De Vos, Reg. No. 37,813; Scott A. Griffin, Reg. No. 38,167; Stephen D. Gross, Reg. No. 31,020; David R. Halvorson, Reg. No. 33,395; Michael D. Hartogs, Reg. No. 36,547; Brian D. Hickman, Reg. No. 35,894; George W. Hoover II, Reg. No. 32,992; Paul H. Hostmann, Reg. No. 36,167; Eric S. Hyman, Reg. No. 30,139; Dag H. Johansen, Reg. No. 36,172; Stephen L. King, Reg. No. 19,180; Joseph T. Lin, Reg. No. 38,225; Michael J. Mallie, Reg. No. 36,591; James D. McFarland, Reg. No. 32,544; Anthony C. Murabito, Reg. No. 35,295; Kimberley G. Nobles, Reg. No. 38,255; Ronald W. Reagin, Reg. No. 20,340; Kent R. Richardson, Reg. No. P-39,443; James H. Salter, Reg. No. 35,668; William W. Schaal, Reg. No. P-39,018; James C. Sheller, Reg. No. 31,195; Edward W. Scott IV, Reg. No. 36,000; Maria E. Sobrino, Reg. No. 31,639; Stanley W. Sokoloff, Reg. No. 25,128; Allan T. Sponseller, Reg. No. 38,318; John C. Stattler, Reg. No. 36,285; Edwin H. Taylor, Reg. No. 25,129; Lester J. Vincent, Reg. No. 31,460; Ben J. Yorks, Reg. No. 33,609; and Norman Zafman, Reg. No. 26,250; my attorneys; and William D. Davis, Reg. No. 38,428; Gary B. Goates, Reg. No. 35,159; Soyeon P. Laub, Reg. No. P-39,266; Thomas X. Li, Reg. No. 37,079; and Edwin A. Sloane, Reg. No. 34,728; my patent agents, with offices located at 12400 Wilshire Boulevard, 7th Floor, Los Angeles, California 90025, telephone (310) 207-3800, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole/First Inventor: ORY, Joël

Inventor's Signature: 


Date: 4.11.2001

Residence: MONTPELLIER / FR
(City, State) FRX

Citizenship: FRANCE
(Country)

Post Office Address: Lot Château Bon, 40, place Gaby Morlay 34070 MONTPELLIER / FR

Full Name of Second/Joint Inventor: PUY, Jean-Yves

Inventor's Signature: 


Date: 4.11.2001

Residence: MONTPELLIER / FR
(City, State) FRX

Citizenship: FRANCE
(Country)

Post Office Address: Résidence Le Gauguin A1, 75, avenue du Pont Trinquat 34070 MONTPELLIER / FR

300 Full Name of Third/Joint Inventor: IMBACH, Jean-Louis

Inventor's Signature: FRX 


Date: 4.11.2001

Residence: MONTPELLIER / FR
(City, State)

Citizenship: FRANCE
(Country)

Post Office Address: 91, impasse de Luques 34000 MONTPELLIER / FR

100 Full Name of Fourth/Joint Inventor: CLAYETTE, Pascal

Inventor's Signature: FRX 


Date: 4.11.2001

Residence : VERSAILLES / FR
(City, State)

Citizenship: FRANCE
(Country)

Post Office Address: 17, rue Edmé Fremy 78000 VERSAILLES / FR

500 Full Name of Fifth/Joint Inventor: FRETIER, Philippe

Inventor's Signature: FRX 


Date: 4.11.2001

Residence : NOGENT SUR MARNE / FR
(City, State)

Citizenship: FRANCE
(Country)

Post Office Address: 20, avenue Duvelleroy 94130 NOGENT SUR MARNE / FR

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

** Scanned copy is best available. most of the drawings are done.*